A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Large cells, usually multinucleate, whose presence is a common histologic characteristic of classical HODGKIN DISEASE.
A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B and APOPTOSIS. They are found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; NEUTROPHILS; EOSINOPHILS; MAST CELLS and NK CELLS. Overexpression of CD30 antigen in hematopoietic malignancies make the antigen clinically useful as a biological tumor marker. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA.
An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564)
Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.
Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
A general term for various neoplastic diseases of the lymphoid tissue.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Elements of limited time intervals, contributing to particular results or situations.
The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies.
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)
Lists of words, usually in alphabetical order, giving information about form, pronunciation, etymology, grammar, and meaning.
A hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC 3.5.1.1.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
Component of the NATIONAL INSTITUTES OF HEALTH. Through basic and clinical biomedical research and training, it conducts and supports research into the nature of the aging process and diseases associated with the later stages of life. The Institute was established in 1974.
NATIONAL LIBRARY OF MEDICINE service for health professionals and consumers. It links extensive information from the National Institutes of Health and other reviewed sources of information on specific diseases and conditions.
The external junctural region between the lower part of the abdomen and the thigh.
Procedures for recognizing individual animals and certain identifiable characteristics pertaining to them; includes computerized methods, ear tags, etc.
Messages between computer users via COMPUTER COMMUNICATION NETWORKS. This feature duplicates most of the features of paper mail, such as forwarding, multiple copies, and attachments of images and other file types, but with a speed advantage. The term also refers to an individual message sent in this way.
Mechanical food dispensing machines.
The guidelines and policy statements set forth by the editor(s) or editorial board of a publication.
The profession of writing. Also the identity of the writer as the creator of a literary production.
A publication issued at stated, more or less regular, intervals.
The functions and activities carried out by the U.S. Postal Service, foreign postal services, and private postal services such as Federal Express.
A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.
A system of organs and tissues that process and transport immune cells and LYMPH.
Tubular vessels that are involved in the transport of LYMPH and LYMPHOCYTES.

Intensive investigation in management of Hodgkin's disease. (1/3116)

Ninety-eight patients with clinically localised Hodgkin's disease underwent laparotomy and splenectomy to determine the extent of microscopic spread. In 68 patients the procedure was carried out for untreated disease apparently confined above the diaphragm. Abdominal disease cannot be confidently excluded on the basis of non-invasive investigation at presentation. Clinical assessment of splenic disease was unreliable unless gross splenomegaly was present. Pedal lymphography was accurate in assessing para-aortic and iliac disease but of no value in assessing other intra-abdominal lymph node involvement, including that of the mesenteric lymph node. Trephine bone marrow biopsy findings were normal in all patients before surgery, and only one patient was found to have diseased bone marrow by Stryker-saw biopsy at operation. Liver disease was identified at operation in nine patients, some of whom were asymptomatic with clinically undetectable splenic and nodal disease. Detailed clinical staging failed to detect disease in one-third of patients who underwent laparotomy. These studies show that if radiotherapy is to remain the treatment of choice for disease truly localised to lymph nodes a detailed staging procedure, including laparotomy and splenectomy, remains essential. The value of this potentially curative treatment is considerably diminished in the patient who has been inadequately staged.  (+info)

Prednisone in MOPP chemotherapy for Hodgkin's disease. (2/3116)

High remission rates have been produced by MOPP (mustine, vincristine, procarbazine, and prednisone) chemotherapy in patients with advanced Hodgkin's disease, but the prednisone component has caused adverse effects in patients who have undergone radiotherapy. The remission rates and length of remission were reviewed in 211 patients with Hodgkin's disease who received chemotherapy either with or without prednisone. In contrast to the findings of a British study, there were no significant differences in remission rates or length of remission between patients who had received prednisone and patients who had not. There were differences between the British prospective study and this retrospective one, but it is difficult to know what accounted for the substantial differences in the findings.  (+info)

Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. (3/3116)

PURPOSE: Recent studies have suggested that lymphocyte-predominant Hodgkin's disease (LPHD) is both clinically and pathologically distinct from other forms of Hodgkin's disease, including classical Hodgkin's disease (CHD). However, large-scale clinical studies were lacking. This multicenter, retrospective study investigated the clinical characteristics and course of LPHD patients and lymphocyte-rich classical Hodgkin's disease (LRCHD) patients classified according to morphologic and immunophenotypic criteria. MATERIALS AND METHODS: Clinical data and biopsy material of all available cases initially submitted as LPHD were collected from 17 European and American centers, stained, and reclassified by expert pathologists. RESULTS: The 426 assessable cases were reclassified as LPHD (51%), LRCHD (27%), CHD (5%), non-Hodgkin's lymphoma (3%), and reactive lesion (3%); 11% of cases were not assessable. Patients with LPHD and LRCHD were predominantly male, with early-stage disease and few risk factors. Patients with LRCHD were significantly older. Survival and failure-free survival rates with adequate therapy were similar for patients with LPHD and LRCHD, and were stage-dependent and not significantly better than stage-comparable results for CHD (German trial data). Twenty-seven percent of relapsing LPHD patients had multiple relapses, which is significantly more than the 5% of relapsing LRCHD patients who had multiple relapses. Lymphocyte-predominant Hodgkin's disease patients had significantly superior survival after relapse compared with LRCHD or CHD patients; however, this was partly due to the younger average age of LPHD patients. CONCLUSION: The two subgroups of LPHD and LRCHD bore a close clinical resemblance that was distinct from CHD; the course was similar to that of comparable nodular sclerosis and mixed cellularity patients. Thorough staging is necessary to detect advanced disease in LPHD and LRCHD patients. The question of how to treat such patients, either by reducing treatment intensity or following a "watch and wait" approach, remains unanswered.  (+info)

Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. (4/3116)

PURPOSE: To determine the treatment outcome and clinical factors that are of prognostic significance for children and adolescents with relapsed or refractory Hodgkin's disease (HD) who received treatment with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation (HSCT). PATIENTS AND METHODS: Fifty-three consecutive children and adolescents 21 years of age or younger with relapsed or refractory HD underwent HSCT. RESULTS: At day 100 after transplantation, 29 patients (55%) were in a complete remission or maintained a continuous complete response, six (11%) had a partial response, and 11 (21%) failed to respond or had progressive disease. The failure-free survival (FFS) at 5 years was 31%, and overall survival was 43%. Twenty-one patients died of progressive HD, and nine died secondary to transplantation-related complications, including two secondary leukemias. Prognostic factors important for FFS were normal pretransplantation lactate dehydrogenase levels (5-year FFS = 42%), compared with patients with elevated LDH levels (5-year FFS = 0%) (P < .001), and disease sensitivity at the time of HSCT with FFS in untreated relapse, sensitive disease, and resistant disease 44%, 35%, and 9%, respectively (P = .06). There was no statistically significant difference in FFS or overall survival between age subgroups that were analyzed (< 13, 13 to 18, 19 to 21) or in comparison with an adult cohort. CONCLUSION: HSCT is an effective treatment modality that can result in long-term cures and should be considered for children and adolescents with relapsed HD.  (+info)

Reduced health-related quality of life among Hodgkin's disease survivors: a comparative study with general population norms. (5/3116)

BACKGROUND: Late complications after curative treatment of Hodgkin's disease are of special relevance because most of the cured are young adults. The aims of the present study were: (1) to compare health-related quality of life (HRQOL) in Hodgkin's disease (HD) survivors with normative data from the general Norwegian population and (2) to examine the relations between disease/treatment characteristics and HRQOL in the HD survivors. PATIENTS AND METHODS: 459 HD survivors aged 19-74 years (mean 44.0, SD 11.8) treated at the Norwegian Radium Hospital 1971-1991 were approached in 1994 and compared to norms from 2214 subjects approached in 1996. The norms are representative of the general Norwegian population. HRQOL was assessed by the Short Form 36 (SF-36), which measures HRQOL in eight separate scales (0 = worst health state, 100 = best health state). RESULTS: The HD survivors had lower scores than the normal controls on all scales after adjustment for age, gender and educational levels. Statistically significant differences (P < 0.01) were found in general health (10.4), physical functioning (6.1), role limitations (physical, 9.3), physical functioning (3.6) and in vitality (4.7). Patients with disease stage IB-IIB had the lowest scores on all scales. The differences in relation to stage/substage reached statistical significance (P < 0.01) in physical functioning and in role limitations (physical). Time since diagnosis, types of primary treatment or having relapsed were not associated with statistically significant differences in HRQOL. CONCLUSION: Long-term HD survivors have poorer HRQOL, primarily in physical health, than the general Norwegian population.  (+info)

Bone marrow scintigraphy using technetium-99m antigranulocyte antibody in malignant lymphomas. (6/3116)

BACKGROUND: The purpose of this study was to elucidate the clinical reliability of immunoscintigraphy (IS) to detect infiltration of the bone marrow in patients with malignant lymphoma. PATIENTS AND METHODS: Whole body IS was performed in 103 patients with Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL) using Tc-99m labelled anti-NCA-95 which allows visualization of the granulopoietic bone marrow. Of these, 52% were studied prior to any therapy. Findings were compared to posterior iliac crest biopsy as well as MRI and/or follow-up examination. Criteria of marrow infiltration were a positive biopsy, positive follow-up, or positive results of MRI. RESULTS: Comparison of IS and biospy revealed concordant findings in 69 and discordant findings in 34 of 103 patients. Of the 34 patients with discordant results, IS showed lesions suspicious of bone marrow infiltration in 29 patients despite normal biopsy findings. When follow-up and additional examinations were taken into consideration, 10 patients remained with probably false positive and five with false negative IS findings. IS proved to be highly sensitive and specific in patients with HD (100% and 84%, respectively) and high-grade NHL (93% and 84%, respectively). Moderate sensitivity (60%) was found in low-grade NHL. This was possibly due to false negative IS in three to five patients with chemotherapy in contrast to one of five false negative results in patients without chemotherapy. CONCLUSION: Bone marrow scintigraphy using antigranulocyte antibodies is highly sensitive in HD and high-grade NHL. Positive findings in IS subsequent to a negative biopsy should be followed by guided re-biopsy or MRI.  (+info)

Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. (7/3116)

PURPOSE: Hodgkin's disease patients who never achieve complete remission with conventional chemotherapy (i.e., those with primary induction failure) have a poor prognosis. Some subjects who receive high-dose therapy with autologous hematopoietic progenitor-cell infusion experience prolonged progression-free survival. PATIENTS AND METHODS: Detailed records from the Autologous Blood and Marrow Transplant Registry (ABMTR) on 122 Hodgkin's disease patients who failed to achieve complete remission after one or more conventional therapy regimens and subsequently received an autotransplant between 1989 and 1995 were reviewed. RESULTS: Median age was 27 years (range, 7 to 57 years). Median time from diagnosis to transplantation was 14 months (range, 5 to 38 months). Most patients received high-dose chemotherapy without radiation for pretransplantation conditioning (n = 107). The regimen most frequently used was cyclophosphamide, carmustine, and etoposide (n = 47). Fifteen patients received total-body irradiation (n = 15). The graft consisted of bone marrow (n = 86), blood stem cells (n = 25), or both (n = 11). The 100-day mortality was 12% (95% confidence interval, 7% to 19%). Sixty patients (50%) were considered to have achieved complete remission after autotransplantation; 37 of these had negative imaging studies, whereas scan abnormalities of unknown significance persisted in 23 patients. Twenty-seven patients (22%) had no response or progressive disease after transplantation. Probabilities of progression-free and overall survival at 3 years were 38% (95% confidence interval, 28% to 48%) and 50% (95% confidence interval, 39% to 60%), respectively. In multivariate analysis, "B" symptoms at diagnosis and poor performance score at transplantation were adverse prognostic factors for outcome. CONCLUSION: Autotransplants should be considered for patients with Hodgkin's disease who do not achieve complete remission with conventional therapy.  (+info)

Stimulation of autologous blood lymphocytes by malignant lymphoma cells and homogenates. (8/3116)

The blastogenic response to autologous blood lymphocytes to whole-cell suspensions and to homogenates obtained from malignant lymphoma tissue has been investigated. Spleens were obtained from patients in whom laparotomy was performed for staging of malignant lymphoma. Cell suspensions prepared from tumour nodules were treated with mitomycin C and allowed to react with separated autologous blood lymphocytes for 6 days. Lymphocyte stimulation was measured by liquid scintillation counting after exposure to 3H-TdR. Cultures were also prepared in which autologous lymphocytes were treated with spleen tumour homogenate. Control experiments used spleens from staging procedures in which no tumour deposits were present, and normal spleens removed incidentally during other operations. In the controls, the uptake of TdR was never more than twice that of unstimulated lymphocytes. Greater degrees of lymphocyte stimulation were seen in 6 out of 14 patients, using whole tumour cells, and in 7 out of 16 patients, using tumour homogenates. The results indicate an antigenic difference between tumour and host cells, and suggest that lymphocytes can react to a tumour-associated antigen.  (+info)

article{f1d460a6-1694-4cd3-a657-b01df9443c91, abstract = {,p,Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent CD20,sup,+,/sup, lymphoma. Its scarcity has made clinical trials difficult and there is no consensus on first-line treatment. We conducted a population-based study of all patients diagnosed with NLPHL in Sweden between 2000 and 2014 (N = 158; 41 women and 117 men), focusing on clinical features, therapy and overall survival. The median female and male age was 59 and 44 years, respectively (P = 0·002). In early-stage disease, there was little mortality and no survival differences between therapies. In patients with advanced-stage disease, mortality was relatively high in patients who did not receive first-line rituximab but absent in those who did (10-year survival, 55% vs. 100%; P = 0·033); there were no imbalances of prognostic factors between those two groups. In advanced stages, first-line rituximab use increased markedly between 2000-2004 and 2005-2014 (7% vs. ...
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon subtype of Hodgkin lymphoma (HL). This disorder is differentiated from all other forms of HL, which are commonly referred to as classical Hodgkin lymphomas (cHLs), by characterist
TJMayer - Patient: Hodgkin Disease > Nodular lymphocyte predominant Hodgkin disease Patient Info: Living with cancer as a chronic illness (undergoing adjuvant therapy), Diagnosed: almost 11 years ago, Male, Age: 61, Stage III
Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) accounts for about 5% of cases. The cancer cells in NLPHL are large cells called popcorn cells (because they look like popcorn), which are variants of Reed-Sternberg cells. You may also hear these cells called lymphocytic and histiocytic (L&H) cells. NLPHL usually starts in lymph nodes in the neck and under the arm. It can occur in people of any agge, and is more common in men than women. This type of Hodgkin lymphoma tends to grow more slowly and is treated differently from the classic types.. ...
Diagnosis Code C81.0 information, including descriptions, synonyms, code edits, diagnostic related groups, ICD-9 conversion and references to the diseases index.
This is the official approximate match mapping between ICD9 and ICD10, as provided by the General Equivalency mapping crosswalk. This means that while there is no exact mapping between this ICD10 code C81.00 and a single ICD9 code, 201.40 is an approximate match for comparison and conversion purposes. ...
Quick overview of NLPHL This section is an overview of the information on this page. There is more detail in the sections below. What is it? NLPHL is a rare, slow-growing type of lymphoma. It is a type of cancer where the abnormal cells are lymphocytes (a type of white blood cell).
Nodular lymphocyte predominant Hodgkins lymphoma (NLPHL) is an indolent CD20(+) form of lymphoma. Some people no longer classified it as a form of classic Hodgkins lymphoma (HL). This is because the Reed-Sternberg cell (RSC) variants (popcorn cells) that characterize this form of the disease invariably express B lymphocyte markers such as CD20 (thus making NLPHL an unusual form of B cell lymphoma), and that (unlike classic HL) NLPHL may progress to diffuse large B cell lymphoma. There are small but clear differences in prognosis between the various forms. Lymphocyte predominant HL is an uncommon subtype composed of vague nodules of numerous reactive lymphocytes admixed with large popcorn-shaped RSC. Unlike classic RSC, the non-classic popcorn-shaped RS cells of NLPHL are CD15 and CD30 negative while positive for the B cell marker CD20. The anti-CD20 monoclonal antibody Rituximab has been used in lymphocyte predominant Hodgkins lymphoma with encouraging results. BCL6 gene rearrangements have ...
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare lymphoma entity with an incidence of 0.1 to 0.2/100 000/y. Compared with the more common subtypes of classical Hodgkin lymphoma, NLPHL is characterized by distinct pathological and clinical features. Histologically, the disease-defining lymphocyte predominant cells consistently express CD20 but lack CD30. Clinically, NLPHL mostly has a rather indolent course, and patients usually are diagnosed in early stages. The prognosis of early-stage NLPHL is excellent, with progression-free survival and overall survival rates exceeding 90% after involved-field radiotherapy (IF-RT) alone (stage IA) or combined modality treatment consisting of a brief chemotherapy with 2 cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy followed by IF-RT (early stages other than stage IA ...
PURPOSE: Classic Hodgkin lymphoma is highly curable with contemporary therapy. Although the limited role of surveillance imaging to detect early relapse for patients in complete remission at the end of therapy is well established, there is a paucity of data regarding role of laboratory testing in this setting.. METHODS: Patients with newly diagnosed classic Hodgkin lymphoma uniformly treated with the Stanford V regimen from 1998-2014 and in complete remission for at least 3 months were identified in a single-center institutional database. Laboratory tests categorized by Common Terminology Criteria for Adverse Events v4.03 as grade 2 or higher were considered abnormal. Primary analysis included sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of surveillance laboratory tests for predicting relapse in the first 3 years after end of treatment.. RESULTS: Among 235 eligible patients, 24 (10.2%) patients ultimately relapsed. In the first 3 years after end ...
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an indolent lymphoma, but can transform into diffuse large B cell lymphoma (DLBCL), showing a more aggressive clinical behavior. Little is known about these cases on the molecular level. Therefore, the aim of the present study was to characterize DLBCL transformed from NLPHL (LP-DLBCL) by gene expression profiling (GEP). GEP revealed an inflammatory signature pinpointing to a specific host response. In a coculture model resembling this host response, DEV tumor cells showed an impaired growth behavior. Mechanisms involved in the reduced tumor cell proliferation included a downregulation of MYC and its target genes. Lack of MYC expression was also confirmed in 12/16 LP-DLBCL by immunohistochemistry. Furthermore, CD274/PD-L1 was upregulated in DEV tumor cells after coculture with T cells or monocytes and its expression was validated in 12/19 cases of LP-DLBCL. Thereby, our data provide new insights into the pathogenesis of LP-DLBCL and an ...
steveo - Survivor: Hodgkin Disease > Classic Hodgkin Disease > Nodular sclerosing Patient Info: Finished active treatment more than 5 years ago, Diagnosed: almost 18 years ago, Male, Age: 32
Preclinical studies suggest that HRS cells evade immune detection by exploiting the pathways associated with immune checkpoint, Programmed Death-1 (PD-1) and its ligands PD-L. Classical Hodgkin Lymphoma is an excellent example of how the tumor microenvironment influences cancer cells to proliferate and survive. The most common genetic abnormality in Nodular sclerosis subtype of Hodgkin lymphoma is the selective amplification of genes on the short arm of chromosome 9 (9p24.1) which includes JAK-2, with resulting increased expression of PD-1 ligands such as PDL1 and PDL2 on HRS cells, as well as increased JAK-STAT activity, essential for the proliferation and survival of Hodgkin Reed-Sternberg (HRS) cells. Infection with Epstein-Barr virus (EBV) similarly can increase the expression of PDL1 and PDL2 in EBV-positive Hodgkin lymphomas. It would therefore seem logical to block or inhibit immune check point PD-1 rather than both its ligands, PDL1 and PDL2.. Immune checkpoints are cell surface ...
Hodgkin lymphoma is cancer that begins in the lymph system in white blood cells called lymphocytes. When these cells become abnormal, they grow without control and may form lumps of tissue called tumors.. The most common type of Hodgkin lymphoma is called classical Hodgkin lymphoma. The cancerous tumors (lymphomas) in classical Hodgkin lymphoma contain Reed-Sternberg cells. Non-Hodgkin lymphomas dont have these cells.. Symptoms of Hodgkin lymphoma include enlargement of the lymph nodes, fever, appetite loss, weight loss, and night sweats.. Hodgkin lymphoma affects men more often than women. The cause of Hodgkin lymphoma is not known.. Treatment for Hodgkin lymphoma depends on the stage of the lymphoma and may include radiation or chemotherapy.. ...
Interventions for early stage Hodgkins disease in children: Cochrane systematic review answers are found in the Cochrane Abstracts powered by Unbound Medicine. Available for iPhone, iPad, Android, and Web.
Scientists at the Queensland Institute of Medical Research have discovered that a simple blood test can determine how well chemotherapy is working in Hodgkin lymphoma patients.. The discovery by Professor Maher Gandhi and Kimberley Jones from QIMRs Clinical Immunohaematology Laboratory could mean personalised treatment for patients with the blood cancer.. This has the potential to be a huge aid for doctors in their decision making and a faster and less invasive process for the patients, Professor Gandhi said.. Up until now, clinicians have relied on scans to help them judge how well people are responding to chemotherapy. The imaging is expensive, it can be difficult to interpret, and can be limited to just one scan before treatment starts, and another when treatment is finished.. This discovery means we can work towards using simple blood tests to provide quicker, cheaper, and more regular monitoring of how a person is responding to treatment.. About 400 Australians are diagnosed with ...
A new cancer drug with remarkably few side effects is dramatically improving survival in Hodgkin lymphoma patients who fail other treatments and are nearly out of options.
2.1.1.1 All patients must have a pathologically confirmed diagnosis of classical Hodgkins lymphoma (HL) as outlined in the World Health Organization (WHO) Classification System of Lymphoid Tumours. Patients with nodular lymphocyte-predominant Hodgkins lymphoma (HL) (NLPHL) are not eligible.. 2.1.1.2 Refractory or relapsed HL patients that are also candidates for auto stem cell transplant (ASCT).. 2.1.1.3 At least one adverse prognostic factor: (1) initial relapse less than or equal to 12 months after primary chemotherapy, (2) staged as Ann Arbor Classification initial stage III or IV disease, (3) chemotherapy resistant disease, (4) Failure to achieve a complete response (CR) with cytoreductive chemotherapy or persistent positive (18) fluorodeoxyglucose positron emission tomography (FDGPET) imaging.. 2.1.1.4 At least 10% of the cells obtained from lymph node, or extranodal sites must react with anti-cluster of differentiation 25 (CD25) (anti-Tac) on immunofluorescent or immunoperoxidase ...
Paraffin sections from a series of 50 lymph nodes affected by Hodgkins disease were examined by means of the unlabelled primary antibody peroxidase-antiperoxidase method to detect those cells which contained S-100 protein. In addition, 15 lymph nodes showing reactive follicular hyperplasia were studied. A simple enumeration procedure (eyepiece graticule) was used to count the number of such cells in 20 standard 25 X microscope fields. In the specimens of nodular sclerosing Hodgkins disease many cells positive for S-100 protein were present, in contrast to the other Rye subtypes, which showed a relative paucity. By comparison, the lymph nodes showing reactive follicular hyperplasia contained a similar number of cells containing S-100 to those seen in the nodular sclerosing lymph nodes affected by Hodgkins disease.. ...
Patients receive doxorubicin hydrochloride 50 mg/m2 IV over 10-30 minutes and cyclophosphamide 800 mg/mg2 IV over 1 hour on day 1, vincristine sulfate 1.4 mg/m2 IV (2.8 mg maximum) over 1 minute on days 1 and 8, and prednisone 40 mg/m2/day PO or IV two or three times daily on days 1-7. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve CR after 3 courses of therapy proceed to follow-up. Patients who do not achieve a CR proceed to involved-field radiation therapy (IFRT).. IFRT: Beginning within 3 weeks after completion of combination chemotherapy, patients undergo IFRT once daily, 5 days a week for 2.8 weeks (14 treatments). ...
TY - JOUR. T1 - Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab. AU - Villasboas Bisneto, Jose (J.C.). AU - Ansell, Stephen Maxted. PY - 2016/1/2. Y1 - 2016/1/2. N2 - Cancer cells are able to escape surveillance from the immune system by co-opting physiologic mechanisms such as the programmed cell death-1 (PD-1) receptor pathway. Agents able to block the interaction between the PD-1 receptor and its ligands have the potential to release T cells from tumor-induced suppression and eradicate malignant cells. Nivolumab-a PD-1 inhibitor-is approved for the treatment of patients with metastatic melanoma and lung cancer. This agent has been tested in patients with advanced Hodgkin lymphoma (HL) and showed impressive results in a phase I trial. Here we review the profile of Nivolumab including its pharmacological properties, clinical efficacy and safety in patients with advanced classical HL.. AB - Cancer cells are able to escape ...
In patients with Hodgkin lymphoma who are at risk for disease progression following autologous stem cell transplantation, early consolidation with brentuximab vedotin (Adcetris) post-transplant significantly improved progression-free survival compared with placebo in the phase III AETHERA trial.1 The median progression-free survival was 43 months for the brentuximab-treated group vs 24 months for the placebo group, representing a significant 43% reduction in the risk of disease progression (P = .001).. In my opinion, once this study is published, brentuximab should be the standard of care for patients with the characteristics in this trial: that is, remission duration less than 1 year, extranodal disease, B symptoms, two or more prior salvage therapies, and primary refractory disease, said lead author Craig Moskowitz, MD, Clinical Director of the Division of Hematologic Oncology at Memorial Sloan Kettering Cancer Center, New York.. Dr. Moskowitz explained that autologous stem cell ...
16 December 2011 Toronto - A Canadian-led clinical trial has found that patients with limited stage Hodgkin lymphoma have better overall survival rates when treated with chemotherapy compared with those receiving extensive radiation. The results were presented at the American Society of Hematology annual meeting and published online by The New England Journal of Medicine.. Currently, patients with limited stage Hodgkin lymphoma receive radiation therapy combined with chemotherapy. While this combination therapy is effective at controlling the disease, patients may experience long-term side effects, such as heart conditions or subsequent cancers, from the radiation. For this study, the researchers recruited 405 patients with limited stage (IA or IIA) Hodgkin lymphoma (HL). The trial participants were divided into favourable- and unfavourable-risk groups and randomized into two treatment arms: those who received the ABVD chemotherapy regimen and those who received radiation therapy (with or ...
Researchers have sequenced the genomes of 10 patients with classical Hodgkin lymphoma (cHL), cataloging the mutations in the Reed-Sternberg (RS) cells that characterize cHL.
The ICD-10 Code C81.73 is the code used for Oth classical Hodgkin lymphoma, intra-abdominal lymph nodes .An alternative description for this code is Other classical Hodgkin lymphoma, intra-abdominal ...
For people with advanced Hodgkin lymphoma, using PET imaging to guide chemotherapy treatment significantly increases the number of people who go into remission.
City of Hope research-led study reports on five-year survival data, suggests that the targeted therapy brentuximab vedotin (BV) should be standard of care for patients with relapsed or treatment-resistant Hodgkin lymphoma.
MONDAY, March 13, 2017 (HealthDay News) -- The risk of developing a second type of cancer may be high among Hodgkin lymphoma survivors, especially those with a family history of cancer. Thats the finding of a new European study in which researchers examined data from more than 9,500 Hodgkin lymphoma patients. Hodgkin lymphoma, once known as Hodgkins disease, is a cancer that starts in the white blood cells called lymphocytes. Lymphocytes are part of the immune system, according to the American Cancer Society.
54 NCCN Guidelines for Patients ® Hodgkin Lymphoma, Version 1.2015 4 Treatment guide: Classical Hodgkin lymphoma Review Review • First-time treatment for classic Hodgkin lymphoma almost always consists of chemotherapy and radiation therapy. Sometimes, chemotherapy alone is given if it works really well. More chemotherapy is given to cancers that are larger or more widespread. • Refractory cancer is cancer that isnt cured during first-time treatment. Chemotherapy is often first used for treatment. If the cancer responds well, you may have a stem cell transplant with or without radiation therapy. If the cancer responds less well, you may receive other drug treatments with or without radiation therapy. Radiation therapy alone is also an option to treat refractory disease following chemotherapy. • A relapse is cancer that re-appears on tests after a cancer-free period. Treatment options for stage IA or IIA depend on whether you had radiation therapy before. If not, chemotherapy with or ...
If Hodgkin lymphoma returns after treatment, you may receive stem cell transplantation. A transplant of your own blood-forming stem cells (autologous stem cell transplantation) allows you to receive high doses of chemotherapy, radiation therapy, or both. The high doses destroy both Hodgkin lymphoma cells and healthy blood cells in the bone marrow.. Stem cell transplants take place in the hospital. Before you receive high-dose treatment, your stem cells are removed and may be treated to kill lymphoma cells that may be present. Your stem cells are frozen and stored. After you receive high-dose treatment to kill Hodgkin lymphoma cells, your stored stem cells are thawed and given back to you through a flexible tube placed in a large vein in your neck or chest area. New blood cells develop from the transplanted stem cells.. ...
Kandukuri Mahesh Kumar1, V. Indira2, Sudhir Kumar Vujhini3 1Assistant Professor, 2Prof & HOD, 3Associate Professor, Department of Pathology, Malla Reddy Institute of Medical Sciences, Suraram, Hyderabad.. Abstract Of all the pediatric malignancies, lymphomas account for about 10-15% of the cases with half of them diagnosed as Hodgkins lymphoma. Remarkably, this malignancy has a high cure rate with a 5-year survival rate approaching 95%. Hodgkins lymphoma has an overall incidence rate of 14 per 100,000 less than 15 years of age. It has a typical bimodal distribution with respect to age. In developed countries, the peak incidence is seen in young adults and the elderly. While, in developing countries the incidence is higher among children and young adults with a male preponderance. Histologically, mixed cellularity subtype of classical Hodgkins lymphoma occurs commonly in the children and in developing countries. We report three typical cases of classical Hodgkins lymphoma, mixed cellularity ...
People with Hodgkin lymphoma may be treated with chemotherapy, radiation therapy, or both.. If Hodgkin lymphoma comes back after the treatment of lymphoma, doctors call this a relapse or recurrence. People with Hodgkin lymphoma that comes back after treatment may receive high doses of chemotherapy, radiation therapy, or both, followed by stem cell transplantation.. Chemotherapy. Chemotherapy for Hodgkin lymphoma uses drugs to kill lymphoma cells. It is called systemic therapy because the drugs travel through the bloodstream. The drugs can reach lymphoma cells in almost all parts of the body.. Usually, more than one drug is given. Most drugs for Hodgkin lymphoma are given through a vein (intravenous), but some are taken by mouth.. Chemotherapy is given in cycles. You have a treatment period followed by a rest period. The length of the rest period and the number of treatment cycles depend on the stage of your disease and on the anticancer drugs used.. You may have your treatment in a clinic, at ...
To prospectively investigate the coronary artery status using coronary CT angiography (CCTA) in patients with Hodgkin lymphoma treated with combined modalities and mediastinal irradiation....
Adult Hodgkin lymphoma treatment (PDQ)-patient version. National Cancer Institute website. Available at: https://www.cancer.gov/types/lymphoma/patient/adult-hodgkin-treatment-pdq. Updated April 12, 2017. Accessed March 30, 2018.. Hodgkin lymphoma. Leukemia & Lymphoma Society website. Available at: http://www.lls.org/lymphoma/hodgkin-lymphoma?src1=20045&src2=. Accessed March 30, 2018.. Hodgkin lymphoma. Merck Manual Professional Version website. Available at: https://www.merckmanuals.com/professional/hematology-and-oncology/lymphomas/hodgkin-lymphoma. Updated October 2012. Accessed March 30, 2018.. Hodgkin lymphoma (HL). EBSCO DynaMed Plus website. Available at:http://www.dynamed.com/topics/dmp~AN~T114957/Hodgkin-lymphoma-HL. Updated November 22, 2017. Accessed March 30, 2018.. What is Hodgkin lymphoma? American Cancer Society website. Available at: https://www.cancer.org/cancer/hodgkin-lymphoma/about/what-is-hodgkin-disease.html. Updated March 28, 2017. Accessed March 30, 2018. ...
TY - JOUR. T1 - A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts. AU - Ghesquières, Hervé. AU - Larrabee, Beth R.. AU - Casasnovas, Olivier. AU - Maurer, Matthew J.. AU - McKay, James D.. AU - Ansell, Stephen M.. AU - Montgomery, Dorothy. AU - Asmann, Yan W.. AU - Farrell, Katrina. AU - Verney, Aurélie. AU - Slager, Susan L.. AU - Allmer, Cristine. AU - Perrot, Aurore. AU - Delarue, Richard. AU - Habermann, Thomas M.. AU - Dupuis, Jehan. AU - Link, Brian K.. AU - Canioni, Danielle. AU - Dogan, Ahmet. AU - Cozen, Wendy. AU - Jarrett, Ruth F.. AU - Cerhan, James R.. AU - Salles, Gilles. PY - 2018/1. Y1 - 2018/1. KW - Hodgkin lymphoma. KW - MYC. KW - PVT1. KW - polymorphism. KW - prognostic. KW - susceptibility. UR - http://www.scopus.com/inward/record.url?scp=85040376800&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=85040376800&partnerID=8YFLogxK. U2 - 10.1111/bjh.14306. DO - ...
This study investigated the toxicity and efficacy of nivolumab as a single agent in the treatment of relapsed or refractory Hodgkins lymphoma (HL) after
3. What are the symptoms of Hodgkin lymphoma? The most common signs of Hodgkin lymphoma are swollen (painless) lymph nodes in the neck, underarm, or groin, as well as fever, night sweats and weight loss. Other symptoms can include itchy skin, fatigue, cough or shortness of breath.. 4. How do doctors diagnose Hodgkin lymphoma? Typically, the doctor will first conduct a physical exam to check for signs of health and any unusual lumps. The doctor will also check routine blood tests and perform scans, such as a CT scan or MRI.. A biopsy of involved tissue or lymph nodes is essential to make a diagnosis. A pathologist then examines the lymph node tissue to look for the malignant B cells.. A doctor may decide to run additional blood tests, including a blood chemistry study and a check for erythrocyte sedimentation rate.. 5. What are the treatment options for Hodgkin lymphoma? There are two main tools used in standard treatment for Hodgkin lymphoma: Chemotherapy and radiation therapy.. Combination ...
TY - JOUR. T1 - Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy. T2 - KEYNOTE-087 subgroup analysis. AU - Zinzani, Pier Luigi. AU - Chen, Robert. AU - Armand, Philippe. AU - Johnson, Nathalie A.. AU - Brice, Pauline. AU - Radford, John. AU - Ribrag, Vincent. AU - Molin, Daniel. AU - Vassilakopoulos, Theodoros P.. AU - Tomita, Akihiro. AU - von Tresckow, Bastian. AU - Shipp, Margaret A.. AU - Lin, Jianxin. AU - Nahar, Akash. AU - Balakumaran, Arun. AU - Moskowitz, Craig H.. PY - 2020/3/20. Y1 - 2020/3/20. UR - http://www.scopus.com/inward/record.url?scp=85078638645&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=85078638645&partnerID=8YFLogxK. U2 - 10.1080/10428194.2019.1702178. DO - 10.1080/10428194.2019.1702178. M3 - Letter. C2 - 31905294. AN - SCOPUS:85078638645. VL - 61. SP - 950. EP - 954. JO - Leukemia and Lymphoma. JF - Leukemia ...
Background. Reports dealing with clinical outcomes of classical Hodgkins lymphoma in low- to middle-income countries are scarce and response to therapy is poorly documented. This report describes the characteristics and clinical outcomes of patients with classical Hodgkins lymphoma from a single institution in Latin America.. Method. A retrospective study was conducted over ten years of patients with classical Hodgkins lymphoma treated at a referral center. Progression-free and overall survival rates were estimated by Kaplan-Meier analysis. The univariate Cox regression model was used to estimate associations between important variables and clinical outcomes.. Main results. One hundred and twenty-eight patients were analyzed. The mean age was 28.5 years. The five-year progression-free and overall survival were 37.3% and 78.9%, respectively. Of the whole group, 55 (43%) were primary refractory cases. Only 39/83 (47%) patients with advanced disease vs. 34/45 (75.6%) in early stages ...
PURPOSE: To assess the effect of more extensive radiotherapy and of adjuvant combination chemotherapy on long-term outcome of early-stage Hodgkins disease. METHODS: In a collaborative worldwide systematic overview, individual patient data were centrally reviewed on 1,974 patients in eight randomized trials of more versus less extensive radiotherapy and on 1,688 patients in 13 trials of radiotherapy plus chemotherapy versus radiotherapy alone. Crude mortality data on 226 patients in two other trials of chemotherapy were also reviewed. RESULTS: More extensive radiotherapy reduced the risk of treatment failure (resistant or recurrent disease) at 10 years by more than one third (31.3% v 43.4% failures; P | .00001), but there was no apparent improvement in overall 10-year survival (77.1 % v 77.0% alive). The addition of chemotherapy to radiotherapy halved the 10-year risk of failure (15.8% v 32.7%; P | .00001), with a small, nonsignificant improvement in survival (79.4% v 76.5% alive). This involved a
PURPOSE: To assess the effect of more extensive radiotherapy and of adjuvant combination chemotherapy on long-term outcome of early-stage Hodgkins disease. METHODS: In a collaborative worldwide systematic overview, individual patient data were centrally reviewed on 1,974 patients in eight randomized trials of more versus less extensive radiotherapy and on 1,688 patients in 13 trials of radiotherapy plus chemotherapy versus radiotherapy alone. Crude mortality data on 226 patients in two other trials of chemotherapy were also reviewed. RESULTS: More extensive radiotherapy reduced the risk of treatment failure (resistant or recurrent disease) at 10 years by more than one third (31.3% v 43.4% failures; P | .00001), but there was no apparent improvement in overall 10-year survival (77.1 % v 77.0% alive). The addition of chemotherapy to radiotherapy halved the 10-year risk of failure (15.8% v 32.7%; P | .00001), with a small, nonsignificant improvement in survival (79.4% v 76.5% alive). This involved a
cHL: Evaluation of 1,450 patients - Higher Absolute Monocyte Count (AMC) is poor predictor of 5-year PFS and 5-year OS in patients with Nodular Sclerosis (NS) classical Hodgkin Lymphoma
The Hodgkins Lymphoma Violet Ribbon Awareness T-Shirt Shop was established in February 2007 by a pair of sisters, one who survived two battles of Hodgkins Lymphoma and the other who saved her life by donating her stem cells for a life saving syngeneic stem cell transplant to help her sister. Through their partnership with Cafepress, they open their shop to help raise awareness for what is deem a rare and easy cancer known as Hodgkins Lymphoma (aka Hodgkins Disease). Through their cancer awareness t-shirts, apparel and merchandise representing Hodgkins Lymphoma Awareness, they hope to bring attention to this rare and misunderstood cancer. The violet ribbon color was chosen in concurrence with the non-profit organization curehodgkins mission and adoption of the Violet Ribbon color in 2001 as the official symbol of unification for Hodgkins Lymphoma, its patients, survivors and their families. They continue the Violet Ribbon Campaigns mission in honor of all those affected by Hodgkins ...
Updated analyses based on long-term follow-up of four German Hodgkin Study Group (GHSG) trials (HD7, HD8, HD10, and HD11) in early stage Hodgkin Lymphoma (HL)
Doctor answers on Symptoms, Diagnosis, Treatment, and More: Dr. Fay on hodgkins lymphoma and emme: Primarily, hodgkins lymphoma teens to spread from one lymph node site to an adjacent site. Non hodgkins lymphoma is more likely to skip lymph node chains to spread distantly. This is why local radiation has historically be more important in the treatment of hodgkins than non hodgkins. for topic: Hodgkins Lymphoma And Emme
Hematology: Hodgkin lymphoma (Hodgkin disease) | Stem cell transplant. Treatment in Aachen, Germany ✈ Find the best medical programs at BookingHealth - ✔Compare the prices ✔Online booking.
Hodgkin lymphoma (Hodgkin disease) | Stem cell transplant. Hematology: Treatment in Frankfurt am Main, Germany ✈. Prices on BookingHealth.com - booking treatment online!
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
Abundant macrophage infiltration in tumors often correlates with a poor prognosis. T cell/histiocyte rich large B cell lymphoma (THRLBCL) is a distinct aggressive B cell lymphoma entity showing a high macrophage content. To further elucidate the role of tumor-associated macrophages in THRLBCL, we performed gene expression profiling of microdissected histiocyte subsets of THRLBCL, nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), Piringer lymphadenitis, sarcoidosis, nonspecific lymphadenitis and monocytes from peripheral blood. In a supervised principal component analysis, histiocytes from THRLBCL were most closely related to epithelioid cells from NLPHL, with both types of cells expressing genes related to proinflammatory and regulatory macrophage activity. Moreover, histiocytes from THRLBCL strongly expressed metal-binding proteins like MT2A, by which histiocytes of THRLBCL can be distinguished from the other histiocyte subsets investigated. Interestingly, the validation at the protein ...
TY - JOUR. T1 - Persistent anticipatory nausea, vomiting, and anxiety in cured Hodgkins disease patients after completion of chemotherapy. AU - Cella, D. F.. AU - Pratt, A.. AU - Holland, J. C.. PY - 1986/1/1. Y1 - 1986/1/1. N2 - Six to 140 months after completion of chemotherapy, 63% of 60 Hodgkins disease survivors experienced anticipatory nausea, 80% had anxiety, and 5% reported vomiting. Time since treatment and treatment severity were significantly associated with pervasiveness of nausea but not of anxiety.. AB - Six to 140 months after completion of chemotherapy, 63% of 60 Hodgkins disease survivors experienced anticipatory nausea, 80% had anxiety, and 5% reported vomiting. Time since treatment and treatment severity were significantly associated with pervasiveness of nausea but not of anxiety.. UR - http://www.scopus.com/inward/record.url?scp=0022596362&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0022596362&partnerID=8YFLogxK. U2 - 10.1176/ajp.143.5.641. DO - ...
In industrialized populations, Hodgkins disease (HD) has an initial peak in young adulthood, whereas in economically developing populations the initial peak occurs in childhood. This pattern resembles that of infection with poliovirus and suggests an infectious cofactor in the etiology. Serologic studies have linked Epstein-Barr virus (EBV) to young adult and adult HD, and viral nucleic acids and antigens have been detected in a subset of Hodgkins tumor specimens. To investigate the association of childhood HD with EBV we studied tumor specimens from 11 children treated in Honduras and 25 children treated in the United States using in situ hybridization and antigen detection techniques. Among the patients from Honduras, tumor specimens from all cases were EBV positive. Among the patients from the United States, tumor specimens from six of seven patients with mixed cellularity histology, 2 of 15 with nodular sclerosis histology, and neither of two patients with lymphocyte-predominant histologies were
Derivation of H/RS cells from mature B cells was previously demonstrated in 18 out of 18 informative unselected cases of cHD analyzed in Cologne and Frankfurt (3)(4)(5)(17)(18)(19). In addition, recent results obtained by others indicate B cell derivation of H/RS cells in 24 out of 25 cases of cHD (20). On the other hand, in a nonselected collection of 13 cases of primary cHD, Daus and colleagues did not detect clonal TCR-γ gene rearrangements in micromanipulated H/RS cells from any of these cases (21). Therefore, these data collectively indicate that cHD represents a homogenous entity as a B cell lymphoma.. However, there are some observations raising the possibility that-in a subset of cHD-the tumor cells might stem from T lymphocytes. Some putative H/RS cell lines, for example, are derived from T cells (2). For these cell lines, proof of derivation from H/RS cells in the patients is missing. Furthermore, a TCR-α gene rearrangement was amplified from whole tissue DNA of lymphomatoid ...
Leukemia & Lymphoma (Contd.) Disease Cause/Risk Factors Symptoms Buzzwords Other Cervical, Supraclavicular or mediastinal nodes Lacunar Reed Sternberg Cells Hodgkins Disease Most common type; affects adolescent or young adult women EBV Variable cell composition & necrosis Collagen Bands (Nodular Sclerosis) Staging (usually I or II) determines treatment; Good prognosis CD15 & CD30 Women Variable cell composition & focal necrosis Hodgkins Disease Disordered fibrosis 2ndEBV Classic Reed Sternberg Cells most common type; men more common (Mixed Cellularity) Eosinophils, Plasma & T Cells Staging determines treatment; Guarded prognosis CD15 & CD30 1) Diffuse Fibrosis - RS Cells embedded in Fairly common - usually in older patients Poor Prognosis Hodgkins Disease fibrous stroma Often Bone Marrow Involvement (Stage III or IV) EBV Many Reed Sternberg Cells (Lymphocyte Depletion) 2) Reticular - RS Cells in sheets Poor prognosis Bone Marrow ? #s of Reed Sternberg Cells Usually not a true Hodgkins ...
A pilot phase II study with brentuximab vedotin as pre-autologous stem cell transplantation induction therapy in relapsed or refractory Hodgkins lymphoma
Health Canada Approves ADCETRIS® (Brentuximab Vedotin) for the Treatment of Relapsed or Refractory Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell Lymphoma (sALCL)
Nodular sclerosis (or NSHL) is a form of Hodgkins lymphoma that is the most common subtype of HL in developed countries. It affects females slightly more than males and has a median age of onset at ~28 years. It is composed of large tumor nodules with lacunar Reed-Sternberg cell (RS cells) surrounded by fibrotic collagen bands. ...
Hodgkins lymphoma is one of the most common lymphoid cancers, particularly among young adults. Although there have been dramatic improvements in the treatment of Hodgkins lymphoma, leading to high cure rates in some groups, current combination chemotherapy regimes are associated with significant secondary complications in long-term survivors. Furthermore, although a proportion of patients with Hodgkins lymphoma will be cured, there still remains a significant rate of relapse and also a smaller proportion of poor responders who will go on to die of their disease. Therefore, developments in the treatment of Hodgkins lymphoma must be directed at improving cure rates and reducing the burden of secondary complications. In recent years, the underlying pathogenesis of Hodgkins lymphoma has become better understood. In particular, it is emerging that a key pathogenic event in Hodgkins lymphoma is protection from Fas-induced cell death. Recent studies by the authors group, and others, have ...
TY - JOUR. T1 - Thymic epithelial hyperplasia with nodular sclerosis Hogkins disease. AU - Ito, Wataru. AU - Kojima, Kensuke. AU - Fujiwara, Kumi. AU - Nanba, Yasuo. AU - Yoshino, Tadashi. AU - Shinagawa, Katsuji. AU - Ishimaru, Fumihiko. AU - Ikeda, Kazuma. AU - Niiya, Kenji. AU - Tanimoto, Mitsune. PY - 2002/11/1. Y1 - 2002/11/1. N2 - We report a case of simultaneous occurrence of thymic epithelial hyperplasia and Hodgkins disease. A computed tomographic scan of the chest revealed a tumor in the anterior mediastinum and conspicuous swelling of lymph nodes in the upper and lower mediastinum. The anterior mediastinal tumor was histologically diagnosed as thymic epithelial hyperplasia, while the lymph nodes were nodular sclerosis Hodgkins disease. Our findings suggest that thymic hyperplasia might be directly involved in the pathology of at least some cases of Hodgkins disease.. AB - We report a case of simultaneous occurrence of thymic epithelial hyperplasia and Hodgkins disease. A computed ...
An analysis of nonsurgical menopause risk among 2,127 women treated for Hodgkin lymphoma found that risk of premature menopause increased more than 20-fold after ovarian radiotherapy, alkylating chemotherapy other than dacarbazine, or BEAM (carmustine [BiCNU], etoposide, cytarabine, melphalan) chemotherapy for stem cell transplantation but was not statistically significantly raised after ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). Results were reported in the Journal of the National Cancer Institute by Anthony J. Swerdlow, DSc, of the Institute of Cancer Research, Surrey, United Kingdom, and colleagues in the England and Wales Hodgkin Lymphoma Follow-up Group.. The authors concluded that patients treated for Hodgkin lymphoma need to plan intended pregnancies using personalized information on their risk of menopause by different future time points and provided tables to give individualized information to women based on the type of treatment, dose, and age at treatment.. The women ...
Hodgkin disease is a type of lymphoma, cancer of the lymph system. It is a rare; but serious condition. Can cause swelling in neck, armpits or groin.
Question - In remission from IIB nodular, sclerosing Hodgkins, have recurring lump on groin, diagnosed as lipoma. Diagnosis correct?. Ask a Doctor about diagnosis, treatment and medication for Lipoma, Ask a Dermatologist
Hodgkin lymphoma was first described in an 1832 report by Thomas Hodgkin, although Hodgkin noted that perhaps the earliest reference to the condition was provided by Marcello Malpighi in 1666.[51][13] While occupied as museum curator at Guys Hospital, London, Hodgkin studied seven with painless lymph node enlargement. Of the seven cases, two were under the care of Richard Bright, one was of Thomas Addison, and one was of Robert Carswell.[51] Carswells report of this seventh person was accompanied by numerous illustrations that aided early descriptions of the disease.[52]. Hodgkins report on these seven people, entitled On some morbid appearances of the absorbent glands and spleen, was presented to the Medical and Chirurgical Society of London in January 1832 and was subsequently published in the societys journal, Medical-Chirurgical Society Transactions.[51] Hodgkins paper went largely unnoticed, however, even despite Bright highlighting it in an 1838 publication.[51] Indeed, Hodgkin ...
TY - JOUR. T1 - Primary intracerebra Hodgkins disease mimicking meningioma. T2 - Case report. AU - Johnson, Mahlon D.. AU - Kinney, Marsha C. AU - Scheithauer, Bernd W.. AU - Briley, Randall J.. AU - Hamilton, Kathy. AU - McPherson, Warren F.. AU - Barton, John H.. PY - 2000. Y1 - 2000. N2 - OBJECTIVE AND IMPORTANCE: A rare case of dura-based primary cerebral Hodgkins disease clinically and radiographically indistinguishable from a meningioma is described. CLINICAL PRESENTATION: A 55-year-old immunocompetent woman presented with headaches and ataxia. Magnetic resonance images demonstrated a circumscribed diffusely enhancing mass with a dural tail attached to the cerebellar tentorium. INTERVENTION: Operation inspection also suggested a meningioma, but a frozen section of the firm mass revealed an inflammatory lesion. Subsequent pathological analysis demonstrated Hodgkins disease, nodular sclerosing type. An extensive workup revealed no systemic disease. CONCLUSION: This case illustrates the ...
Despite a high clinical success, relapse in Hodgkin lymphoma occurs in 10–30% of cases and 5–10% patients are nonresponsive to initial chemotherapy. The standard management of these patients includes high-dose chemotherapy followed by autologous stem cell transplant. However, 50% of patients ultimately relapse after autotransplant which poses a big challenge. Allogeneic stem cell transplantation offers the only chance of cure in these patients. For patients who are not candidates for allogeneic stem cell transplantation, achieving cure with other possible options is highly unlikely, and thus the treatment plan becomes noncurative. Various novel agents have shown promising results but the duration of response is short lived. A standard approach to deliver the most effective treatment for these patients is still lacking. This review focuses on the treatment options currently available for relapsed and refractory disease after autotransplant.
Immunologic studies were done on 47 long-term survivors of Hodgkins disease who had been treated with MOPP chemotherapy (mechlorethamine, vincristine, procarbazine, and prednisone). Percentages of E rosettes and mitogen-induced lymphocyte proliferation were significantly reduced compared to those in normal control subjects. There was no tendency for these abnormalities to return to the normal range with increasing disease-free intervals. No abnormalities of B-cell number or function were detected. Long-term survivors of advanced diffuse histiocytic lymphoma treated with comparable chemotherapy, who served as a control population, had significantly higher percentages of E rosettes and no reduction in mitogen-induced lymphocyte proliferation. Thus these persistent immunologic abnormalities cannot be attributed to chemotherapy alone. The presence of similar immunologic abnormalities in untreated patients with Hodgkins disease of all stages and in patients cured by either MOPP or radiotherapy ...
Forty-one previously treated patients with advanced Hodgkins disease were treated with a combination chemotherapy regimen - ABVD (adriamycin, bl
Most patients with chronic lymphocytic leukemia (CLL) are diagnosed with early stage disease and managed with active surveillance. The individual course of subjects with early stage CLL is heterogeneous and their probability of needing treatment is hardly anticipated at diagnosis. We aimed at developing an international prognostic score to predict time to first treatment (TTFT) in CLL patients with early, asymptomatic disease (IPS-E). Individual patient data from 11 international cohorts of patients with early stage CLL (n=4933) were analyzed to build and validate the prognostic score. Three covariates were consistently and independently correlated with TTFT: unmutated IGHV genes, absolute lymphocyte count ,15 x109/l, and presence of palpable lymph nodes. The IPS-E was the sum of the covariates (one point each), and separated low-risk (score 0), intermediate-risk (score 1) and high-risk patients (score 2-3) showing a distinct TTFT. The score accuracy was validated in 9 cohorts staged by the ...
Seattle Genetics Adcetris has received a boost after the US Food and Drug Administrations (FDA) granted the lymphoma drug priority review status.. Adcetris (brentuximab vedotin), an antibody-drug conjugate, was awarded the status based on the results of the phase III ECHELON-1 trial, which had a primary endpoint of an improved PFS in previously untreated advanced classical Hodgkin lymphoma patients.. Data from the trial - which evaluated a combination of Adcetris plus Adriamycin, vinblastine, dacarbazine (ADC) - showed a 23% reduction in the risk of progression, death or need for additional therapy, achieving its primary endpoint.. Clay Siegall, president and chief executive officer of Seattle Genetics, said: We recently reported the primary data from the phase III ECHELON-1 clinical trial in the Plenary Scientific Session of the 2017 ASH annual meeting.. Data from the trial demonstrated superior activity of the Adcetris-containing regimen over standard of care, and we are working with the ...
TY - JOUR. T1 - Treatment Results of Hodgkins Disease from 1977 to 1991 in National Taiwan University Hospital. AU - 雷, 德. AU - 許, 智捷. AU - 鍾, 娜娜. AU - 王, 博民. AU - 黃, 昭源. AU - 丁, 禮莉(Lai-Lei Ting). PY - 1997. Y1 - 1997. N2 - Purpose: To evaluate the response and outcome of patients of Hodgkins disease undergoing different treatment modalities. Materials and Methods: We reviewed clinical records of Hodgkins disease who received chemotherapy (C/T), radiotherapy (R/T) or combined chemotherapy and radiotherapy (CRT) from 1977 to 1991 in National Taiwan University Hospital ( NTUH). The 5-year survival rate (SR) and 5-year freedom from relapse rate (FFR) in different stages were calculated and classified by different treatment modalities. Result: The overall 5-year survival rate (SR) and 5-year freedom from relapse rate (FFR) were summarized for stage I+Ⅱ, Ⅲ and IV diseases. In stage I+Ⅱ diseases, the SR of CIT, RIT and CRT groups were 50%, 60% and 89%; the ...
CHAPTER 102 HODGKIN LYMPHOMA Williams Hematology CHAPTER 102 HODGKIN LYMPHOMA SANDRA J. HORNING Definition and History Etiology and Pathogenesis Origin of the Reed-Sternberg Cell Oncogenes Cytogenetic Studies Association with EBV Association with the Non-Hodgkin Lymphomas Cytokines Immunologic Dysfunction Epidemiology Clinical Features Presenting Manifestations Laboratory Features Differential Diagnosis Therapy, Course, and Prognosis Treatment Modalities Disease Stage…
Purpose: There is evidence that Hodgkin Reed-Sternberg (HRS) cells in classical Hodgkin lymphoma (cHL) could display some molecular and morphologic markers of cellular senescence (CS). We hypothesized that CS mechanisms may have potential prognostic relevance in cHL and investigated whether the expression of the well-established CS biomarkers p21CIP1/WAF1 and p16INK4a by HRS cells might be predictive of the probability of event-free survival (EFS).. Experimental Design: The study analyzed a retrospective cohort of 147 patients and the results were validated on a cohort of 91 patients independently diagnosed and treated in a different institution. p16INK4a and p21CIP1/WAF1 were categorized as dichotomous variables (, or ≥ 30% of HRS cells at diagnosis) and evaluated in univariate and multivariate analysis.. Results: Both molecules were independent prognostic factors. A positive staining of one of the two molecules in more than 30% HRS cells predicted a better EFS (P , 0.01). ...
Hodgkins lymphoma. Why is it always Hodgkins lymphoma? OK, its not always Hodgkins lymphoma, but it frequently is. Whats so frustrating about seeing young people with Hodgkins lymphoma choosing quackery instead of effective medicine is that Hodgkins lymphoma is so treatable for cure. Indeed, even stage IV Hodgkins lymphoma can be cured about 65% of the time. Sofronsky must have had stage III Hodgkins because the story says she had an estimated 80% chance of beating it with standard treatment. Remember, Hodgkins disease is usually treated with a combination of chemotherapy and radiation therapy.. Of course, the problem is the chemotherapy. Of all the treatments for cancer, chemotherapy tends to be what scares people the most. Its understandable. Take breast cancer, for instance, which I treat surgically. Most women operated on for breast cancer undergo fairly small operations, but even for those who undergo mastectomy, the recovery is generally within a month and the pain not long ...
CD30 / TNFRSF8 (Hodgkin & Reed-Sternberg Cell Marker) Antibody - Without BSA and Azide, Mouse Monoclonal Antibody [Clone Ki-1/779 ] validated in IHC, IF, FC (AH12693-100), Abgent
Lymphoma refers to a family of cancers of the lymphatic system, which includes the parts of the immune system responsible for fighting disease and infection. Lymphomas are divided into two categories, Hodgkins and non-Hodgkins.. Hodgkins lymphoma, also known as HL, is a cancer that begins in lymphocytes, the white blood cells responsible for immune system responses. HL begins when a lymphocyte (usually a B cell) becomes abnormal, with the presence of a particular abnormal cell called a Reed-Sternberg cell. (See photo below.). The Reed-Sternberg cell divides to make copies of itself. The new cells divide again and again, making more and more abnormal cells. The abnormal cells dont die when they should, and they dont protect the body from infections or other diseases. Instead, the buildup of extra cells often forms a mass of tissue called a growth or tumor.. HL can start almost anywhere in the body because of the extensive reach of the lymphatic system. Usually, HL is first found in a lymph ...
Fine needle aspiration (FNA) or core needle biopsy. Your doctor may choose this type of biopsy if you have swollen lymph nodes in your neck or armpit. For FNA, the doctor uses a very thin, hollow needle. For a core needle biopsy, the doctor uses a slightly bigger needle. The needle is used to take a small sample of tissue from the lymph node. For tumors deeper in the body, ultrasound or CT scans may be used to help the doctor guide the needle into place. A needle biopsy may not remove enough tissue for the pathologist to see cancerous cells. Or the sample may also be too small to tell the type of lymphoma. Because of this, most doctors dont use a needle biopsy to try to diagnose Hodgkin lymphoma. But there are times when a needle biopsy may be helpful. If you have been diagnosed with Hodgkin lymphoma, your doctor may use this to see if swelling in another part of your body is also lymphoma.. ...
Researchers used interviews to find the most important issues that people with chronic lymphocytic leukaemia, Hodgkin lymphoma or non Hodgkin lymphoma have.
Hodgkin lymphoma is a cancer that causes few deaths in Canada because of effective treatments. Learn about Hodgkin lymphoma statistics in Canadian adults.
Between 11/2010 and 12/2011, 16 pts were included. The trial was closed early because we observed only 5 responses after 4 cycles. Median age was 34 years (18-77). The median number of previous lines was 5 (2-6). Ten pts were primary refractory and 11 were refractory at inclusion. Twelve pts were R/R a median of 5 months after ASCT and 4 pts never had achieved a chemosensitive status. Five pts had also received aloSCT. Twelve pts presented with extranodal disease at inclusion. A total of 110 cycles were administered, with serious (grade ≥ 3) toxicity in 43 cycles (39%). The most frequent serious toxicities were neutropenia (14% of cycles) and thrombocytopenia (7% of cycles). A toxic death was observed after a septic shock in a non neutropenic pt. An ORR of 38% (1 CR and 5 PR) was observed and 10 pts (62%) achieved clinical benefit (response or disease stabilization for more than 6 months). Median progression free survival (PFS) and overall survival (OS) were 7 and 19 months. With a median ...
Hodgkin lymphoma (HL) survivors treated with radiotherapy and/or chemotherapy are known to have increased risks of heart failure (HF), but a radiation dose-response relationship has not previously been derived. A case-control study, nested in a cohort of 2617 five-year survivors of HL diagnosed before age 51 years during 1965 to 1995, was conducted. Cases (n = 91) had moderate or severe HF as their first cardiovascular diagnosis. Controls (n = 278) were matched to cases on age, sex, and HL diagnosis date. Treatment and follow-up information were abstracted from medical records. Mean heart doses and mean left ventricular doses (MLVD) were estimated by reconstruction of individual treatments on representative computed tomography datasets. Average MLVD was 16.7 Gy for cases and 13.8 Gy for controls (Pdifference = .003). HF rate increased with MLVD: relative to 0 Gy, HF rates following MVLD of 1-15, 16-20, 21-25, and ≥26 Gy were 1.27, 1.65, 3.84, and 4.39, respectively (Ptrend | .001). Anthracycline
TY - JOUR. T1 - Radiation-induced coronary artery disease in Hodgkins disease. AU - Miltényi, Zsófia. AU - Keresztes, Katalin. AU - Garai, Ildikó. AU - Édes, István. AU - Galajda, Zoltán. AU - Tóth, László. AU - Illés, Árpád. PY - 2004/1/1. Y1 - 2004/1/1. N2 - Purpose Secondary malignant tumours and cardiovascular complications are of great importance among the late complications after treatment for Hodgkins disease (HD) because they may significantly reduce the patients life expectancy. We report on coronary artery disease (CAD) after treatment for HD. Methods and Materials We present the case of two female patients with HD who received mediastinal irradiation after which complete remission was achieved. In 12 and 19 years after the onset of the disease, control examinations revealed ischaemic heart disease, which was confirmed by coronary arteriography and solved by stent implantation in one of the patients and bypass surgery in the other one. Conclusions Ischaemic heart disease ...
Clinical Definition Hodgkin disease, or Hodgkin s disease, is a malignant neoplasm of lymphoid cells and is one type of lymphoma. It differs from other lymphomas in that it produces abnormal Reed-Sternberg cells. It is characterized by enlargement of the lymph nodes, spleen and possibly liver. Hodgkin disease is divided into two main subtypes based on…. ...
CD30 is a type I transmembrane glycoprotein of the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkins and Reed-Sternberg cells using monoclonal antibody Ki-1. The ligand for CD30 is CD30L (CD153). The binding of CD30 to CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation, and apoptotic cell death. CD30 has a critical role in the pathophysiology of Hodgkins disease and other CD30+ lymphomas. CD30 acts as a costimulatory molecule in thymic negative selection. In addition to its expression on Hodgkins and Reed-Sternberg cells, CD30 is also found in some non-Hodgkins lymphomas (including Burkitts lymphomas), virus-infected T and B cells, and on normal T and B cells after activation. In T cells, CD30 expression is present on a subset of T cells that produce Th2-type cytokines and on CD4+/CD8+ thymocytes that co-express CD45RO and the IL4 receptor. Soluble form of CD30 (sCD30) serves as a marker reflecting Th2 ...
A 25-year-old male with an existing diagnosis activated his CancerCARE benefit. The patient reported a diagnosis of a rare, high-risk subtype of Hodgkins disease. The patient was receiving treatment for this initial diagnosis. Upon activating his CancerCARE® benefit, the patients samples were sent to a Center of Excellence for diagnosis confirmation. The second opinion determined that the patient had classical Hodgkins disease, not the high-risk diagnosis he originally received. With CancerCAREs help, the patients treatment was adjusted and his overall outcome was improved.. ...
Copyright © 2020 Frontline Medical Communications Inc., Parsippany, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.. ...
Hodgkin disease Like other lymphoproliferative disorders, Hodgkin disease may have both specific and nonspecific cutaneous manifestations. Figure 24-3 illustrates a relatively rare event in children with Hodgkin disease: the direct infiltration of malignant cells into the skin. A biopsy analysis of these brownish papules, nodules, and plaques reveals a histology similar to that of affected lymph nodes. These lesions may occasionally ulcerate, and pruritus is a distressing symptom. ...
Thanks everyone. We have received 615000 Naria so far. God will surely bless you all for your kindness. Please continue to donate to reach our target to help this young man, no amount is too small. God will never leave you too. Amen. Treatment for Hodgkin lymphoma. DONATE Today! http://bit.ly/Treatment_Hodgkin_lymphoma. Please help to save this young man.. He started having pains in his hand and a small boil at the side of his neck. we thought it was pimple and will go away.. Soon he begin to have pains, we took him to the hosptal in Lagos Nigeria where he was diagnosed with Neurofibroma type 1.. In 2011 with so much pains he was taken to the hospital where he was diagnosed with Neurofibroma type 2 and a surgical excision was attemted in 14 of july 2011 and failed.. After that a CT scan of the neck shows anterior neck mass that is prominently on the left. The mass is bulky, lobulated and has septal enhancement. The mass extend superiorly to the angle of the mandible with intra-thoracic ...
Visit the Lymphoma Research Foundations dedicated website for people with Hodgkin lymphoma, www.FocusOnHL.org, for additional information on Hodgkin lymphom...
Hodgkin Lymphoma (HL) survivors are at risk for adverse psychosocial events as a result from cancer diagnosis and treatment. Fatigue is one of the most frequently reported long-term symptoms and is of
AFM13 is a RECRUIT-TandAb (CD30xCD16A) for treating Hodgkin Lymphoma by recruiting NK-cells and macrophages to the specific CD30 surface antigen on Reed-Sternberg cells. This redirected immune response leads to potent tumor cell killing. RECRUIT TandAbs are tetravalent and bispecific, and address key deficiencies of monoclonal antibodies such as (i) differential binding to V/F allotypes of CD16A receptor and (ii) non-selective binding to activating CD16A and non-signalling CD16B receptors. Furthermore, RECRUIT-TandAbs have significant advantages over other antibody fragment technologies such as (i) bivalent binding to the targets and, (ii) longer half-life.. AFM13 binds with high affinity to both CD30 and CD16A and is able to rapidly induce lysis of CD30+ cells at picomolar concentrations in the presence of PBMCs. Intensive in vitro characterization demonstrated that AFM13 is specific for the CD16A receptor, which becomes activated only in the presence of tumor cells: there is no systemic ...
Unfortunately, it was not the good cancer and the road to remission was a bumpy one to say the least. It took a rare syngeneic stem cell transplant and almost two years of back-to-back high dose chemotherapy treatment and radiation therapy to bring our sister into remission status. As a family, we experienced this two-year challenging journey right along our sister. This sobering experience inspired us to do something tangible in our sisters honor and in honor of other cancer warriors and survivors to help promote worldwide awareness for Hodgkins Lymphoma, a cancer wrongly deemed the good cancer ...
... formerly designated Hodgkin's disease) and non-Hodgkin lymphoma (abbreviated NHL). It was initially developed for Hodgkin's, ... Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (November 1971). "Report of the Committee on Hodgkin's Disease ... Report of the committee on the staging of Hodgkin's disease. Cancer Res. 1966;26:1310. Mauch, Peter; James Armitage; Volker ... S: is used if the disease has spread to the spleen. E: is used if the disease is "extranodal" (not in the lymph nodes) or has ...
"Every student and every doctor knows that cases of Hodgkin's disease may show a fever that is high for one week and low for the ... Piccin p.48 Mauch, Peter; James Armitage; Volker Diehl; Richard Hoppe; Laurence Weiss (1999). Hodgkin's Disease. Lippincott ... Ree, HJ (1987). "Stromal macrophage-histiocytes in Hodgkin's disease. Their relation to fever". Cancer. 60 (1479): 1479-84. doi ... To count as Pel-Ebstein fever diagnostic workup for Hodgkin's lymphoma would be required as well if that dianosis was not ...
Hodgkin lymphoma typically is treated with radiotherapy alone, as long as it is localized. Advanced Hodgkin disease requires ... Hodgkin lymphoma Classical Hodgkin lymphomas: Nodular sclerosis form of Hodgkin lymphoma Most common type of Hodgkin lymphoma ... A division into Hodgkin and non-Hodgkin lymphomas is used in several of the older classification systems. A Hodgkin lymphoma is ... Non-Hodgkin lymphomas, which are defined as being all lymphomas except Hodgkin lymphoma, are more common than Hodgkin lymphoma ...
Mauch, Peter; James Armitage; Volker Diehl; Richard Hoppe; Laurence Weiss (1999). Hodgkin's Disease. Lippincott Williams & ... In 1880, Pel was appointed Lecturer in Contagious Diseases and Physiological Diagnostics. In 1883 he became a full Professor of ... or that of a separate disease (Ebstein). Pel also discovered what came to be called "Pel's crisis," defined as "Ocular crises ... a cyclical fever that occurs very rarely in individuals who have Hodgkin's Lymphoma. Pel described in the Berliner Klinische ...
... non-Hodgkin lymphoma (NHL); Hodgkin disease; Chronic lymphocytic leukemia (CLL); including hairy cell leukemia and other ... Hodgkin's disease, non-Hodgkin's lymphoma, soft tissue sarcoma, chloracne, porphyria cutanea tarda, peripheral neuropathy, ... On 26 January 2012, the U.S. Center For Disease Control's Agency for Toxic Substances and Disease Registry challenged this with ... This list now includes B cell leukemias, such as hairy cell leukemia, Parkinson's disease and ischemic heart disease, these ...
Mauch, Peter; James Armitage; Volker Diehl; Richard Hoppe; Laurence Weiss (1999). Hodgkin's Disease. Lippincott Williams & ... Nodular sclerosis (or "NSHL") is a form of Hodgkin's lymphoma that is the most common subtype of HL in developed countries. It ... November 2007). "A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell- ... hyaline vascular Castleman's disease: successful response to rituximab and radiotherapy". Eur. J. Haematol. 79 (5): 455-61. doi ...
... interstitial lung disease (e.g., bleomycin) and occasionally secondary neoplasm (e.g., MOPP therapy for Hodgkin's disease). ... Hodgkin's disease. Mustine, vincristine, procarbazine, prednisolone. MOPP. Doxorubicin, bleomycin, vinblastine, dacarbazine. ... A disease resulting from aggressive chemotherapy". Diseases of the Colon and Rectum. 32 (3): 206-9. PMID 2920627. doi:10.1007/ ... Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, ...
... formerly designated Hodgkin's disease) and non-Hodgkin lymphoma (abbreviated NHL). It was initially developed for Hodgkin's, ... S: is used if the disease has spread to the spleen.. *E: is used if the disease is "extranodal" (not in the lymph nodes) or has ... Report of the committee on the staging of Hodgkin's disease. Cancer Res. 1966;26:1310. ... The Ann Arbor classification is named after Ann Arbor, Michigan, where the Committee on Hodgkin's Disease Staging ...
"Hodgkin's Disease - Staging". oncologychannel. Archived from the original on 2008-10-25. Retrieved 2010-10-14. "Breast Cancer ... Systems of staging may differ between diseases or specific manifestations of a disease. Lymphoma: most use Ann Arbor staging ... in Hodgkin's Disease, Stage II indicates affected lymph nodes on only one side of the diaphragm, whereas Stage III indicates ... Because of its high sensitivity, RT-PCR screening for GCC greatly reduces underestimation of disease stage. Researchers hope ...
Thomas Hodgkin (1798-1866), English physician & pathologist; eponymist of Hodgkin's disease. Friedrich Albin Hoffmann (1843- ... William Boog Leishman (1865-1926), English authority on the pathology of human parasitic diseases (see leishmaniasis) George ... Adolf Weil (1848-1916), German physician and pathologist (see Weil's disease). Ronald S. Weinstein (born 1938), American ... Ludvig Hektoen (1863-1951), American researcher on pathology of infectious diseases. Arnold Ludwig Gotthilf Heller (1840-1913 ...
ISBN 978-1-4832-1841-0. G. W. Richter; Kim Solez (22 October 2013). Progress in Hodgkin's Disease. Elsevier Science. ISBN 978-1 ... and Diseases. Elsevier Science. ISBN 978-1-4832-8230-5. Kim Solez (1994). International Review of Experimental Pathology: vol. ...
He was a graduate of Yale University and Johns Hopkins University who would suffer from Hodgkin's Disease. After learning of ... Hoster became a charter member of the Hodgkin's Disease Research Foundation in New York City, serving as the original President ... "Radiotherapy of Hodgkin's disease". Proc R Soc Med. 65 (12): 1109-10. PMC 1644412. PMID 4631266. The National Cyclopaedia of ... There he focused on research of the disease at Ohio State University. He became a professor of medicine and eventually an ...
... relapsed/refractory Hodgkin's disease). In Phase II clinical trials regarding multiple sclerosis and Crohn's disease, ... T-cell-mediated diseases (multiple sclerosis, Crohn's disease, and transplantations such as solid organ transplantation, ...
Longo D, Young R, Wesley M, Hubbard S, Duffey P, Jaffe E, DeVita V (1986). "Twenty years of MOPP therapy for Hodgkin's disease ... Bonadonna, G.; Fossati, V.; De Lena, M. (1978). ": MOPP versus MOPP plus ABVD in Stage IV Hodgkin's disease". Proc. Am. Assoc. ... Prior to the mid-1960s, advanced-stage Hodgkin disease was treated with single-agent chemotherapy, with fairly dismal long-term ... One study found bleomycin lung damage in 18% of patients receiving ABVD for Hodgkin disease. Retrospective analyses have ...
... interstitial lung disease (e.g., bleomycin) and occasionally secondary neoplasm (e.g., MOPP therapy for Hodgkin's disease). ... A disease resulting from aggressive chemotherapy". Diseases of the Colon and Rectum. 32 (3): 206-9. doi:10.1007/BF02554529. ... including Hodgkin's disease) are more sensitive to chemotherapy, as a larger proportion of the targeted cells are undergoing ... hereditary disease, kidney dysfunction, nutritional deficiencies or anemia of chronic disease. Treatments to mitigate anemia ...
Eventually Hodgkin's disease was diagnosed. He made his last recording for Blue Peter from hospital one week before he died. ...
"Arlen Specter's Hodgkin's disease returns". CNN. April 15, 2008. Archived from the original on April 25, 2009. Retrieved April ... "significantly less advanced than his Hodgkin's disease when it was originally diagnosed in 2005." He underwent a second round ... Diagnosed with Hodgkin's lymphoma in early 2005, he continued his work in the Senate while undergoing chemotherapy. He died ... He was diagnosed six weeks earlier with a new form of the disease. On September 7, 2012, he was released from a Philadelphia ...
Rivas C, Oliva H (1974). "Nuclear bodies in Hodgkin's disease". Pathologia Europaea. 9 (4): 297-301. PMID 4457783. Tani E, ... but appear also to be elevated in many autoimmune and cancerous diseases. Nuclear dots are metabolically stable and resistant ... functional roles and cellular signalling in health and disease". Cellular Signalling. 16 (10): 1085-104. doi:10.1016/j.cellsig. ...
"Hodgkin's disease fatal to Vellone." St. Petersburg Times, Aug. 23, 1977". Pro Football Reference: Jim Vellone. ... Jim Vellone abruptly retired from the NFL in 1971 when he discovered he had Hodgkin's lymphoma. He spent the final six years of ... Although managing to live a normal life for some time, Vellone finally succumbed to the cancerous disease on August 21, 1977, a ... Vellone's career and life were cut short due to Hodgkin's lymphoma. Before he joined the pro leagues, Vellone played college ...
Leukemia, Hodgkin's disease, non Hodgkin's. Self-report and parent report. More than one missed dose per month. 35% ... Hodgkin's disease, acute lymphocytic leukemia (ALL). Biological markers. Level lower than expected. 50% ... Health and disease management[edit]. A WHO study estimates that only 50% of patients suffering from chronic diseases in ... Leukemia or non Hodgkin's lymphoma. Level of drug metabolite in urine. Level lower than expected. 33% ...
Some malignancies that have spread to involve the bone marrow, such as leukemia or advanced Hodgkin's disease, also cause ... Weiss RB, Brunning RD, Kennedy BJ (December 1975). "Hodgkin's disease in the bone marrow". Cancer. 36 (6): 2077-83. doi:10.1002 ... Faguet GB (October 1975). "Quantitation of immunocompetence in Hodgkin's disease". The Journal of Clinical Investigation. 56 (4 ... The SARS disease caused lymphocytopenia. Among patients with laboratory-confirmed COVID-19 in Wuhan China through January 29th ...
However, before the start of the 2003 season, he learned he had Hodgkin's disease, and he was forced to sit the season out. ... "Doctors discover Hodgkin's disease has returned". ESPN. May 6, 2005. Retrieved July 22, 2011. "Report: Chiefs trade CB Mark ... Fields learned before the start of the 2005 season that his Hodgkin's had returned, and so he turned down a new contract offer ...
Hors J, Dausset J (1983). "HLA and susceptibility to Hodgkin's disease". Immunol. Rev. 70: 167-92. doi:10.1111/j.1600-065X.1983 ... 1977). "HLA and MLC typing in patients with Hodgkin's disease". Prog. Clin. Biol. Res. 16: 217-27. PMID 143667. Middleton, D.; ... Within the early studies, A1 was found associate with or protected against some infectious diseases. Some diseases found ... Most of the disease risk conferred by A*0101 are represented by either A1 serotype risks, or A1-B8 serotype risk (In Europe A1- ...
Tula died of Hodgkin's Disease in 1963. He married Rina Balter in 1964. They had no children together but were active in the ... Youngner survived many infections as a young child which left him with a lifelong interest in infectious disease. After ... and persistent newcastle disease virus. Youngner is responsible for the first equine influenza vaccine, based upon cold-adapted ... Journal of Infectious Diseases. 131 (4): 467-473. doi:10.1093/infdis/131.4.467. ISSN 0022-1899. PMID 163873. Youngner, J. S.; ...
"Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer ... The two also collaborated to create the MOPP regimen for Hodgkin's lymphoma. As former chair of the Lymphoma Committee of the ... His research career spans many decades as well as several areas of therapeutic agents for the treatment of malignant diseases. ...
CD15 and CD30 : used for Hodgkin's disease. Alpha fetoprotein: for yolk sac tumors and hepatocellular carcinoma. CD117 (KIT): ... a disease characterized by the formation of a specific abnormal tyrosine kinase. Imitanib has proven effective in tumors that ...
Her dissertation was titled CD40 signaling Hodgkin's disease. She came to the National Cancer Institute (NCI) as a postdoctoral ... Annunziata, Christina Messineo (2000). CD40 signaling Hodgkin's disease (Ph.D. thesis). Georgetown University. OCLC 45954730. " ...
He died of Hodgkin's disease in 1989. He was inducted in the Tennessee Sports Hall of Fame in 1976. The Joe C. Davis Professor ...
... in hematological diseases in adults and children. These diseases include Hodgkin's disease and leukaemia. Thiotepa is also used ... Thiotepa is used in the palliation of many neoplastic diseases. The best results are found in the treatment of adenocarcinoma ...
Years later, he twice defeated Hodgkin's disease. He came back to win a U.S. sailing championship at the age of 72. Cohan ... Then, though only one percent of patients get Hodgkin's disease a second time-he found himself in that category. Again, he was ... Nineteen years after winning his Olympic medal, in 1991, he was diagnosed with Hodgkin's disease of the lymph glands and nodes ... List of select Jews in sailing List of Olympic medalists in Dragon class sailing List of select cases of Hodgkin's Disease ...
The early historical roots of the field can be traced to the work of people such as Louis Lapicque, Hodgkin & Huxley, Hubel & ... Adaszewski S1, Dukart J, Kherif F, Frackowiak R, Draganski B; Alzheimer's Disease Neuroimaging Initiative (2013). "How early ... Hodgkin AL, Huxley AF (28 August 1952). "A quantitative description of membrane current and its application to conduction and ... About 40 years later, Hodgkin & Huxley developed the voltage clamp and created the first biophysical model of the action ...
... there he was diagnosed with Hodgkin's disease.[376] In mid-1984, Office 131 was moved to a new base further into Cambodia, near ...
Infectious diseasesEdit. Imaging infections with molecular imaging technologies can improve diagnosis and treatment follow-up. ... As a result, FDG-PET can be used for diagnosis, staging, and monitoring treatment of cancers, particularly in Hodgkin's ... Cardiology, atherosclerosis and vascular disease study: In clinical cardiology, FDG-PET can identify so-called "hibernating ... March 1999). "In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease". Neurology. 52 (4): ...
... and IgG4-related disease.[27] There is some evidence that it is ineffective in treating IgA-mediated autoimmune diseases.[28] ... Rituximab is used to treat cancers of the white blood system such as leukemias and lymphomas, including non-Hodgkin's lymphoma ... and lymphocyte predominant subtype, of Hodgkin's Lymphoma.[12] Autoimmune diseases[edit]. Rituximab has been shown to be an ... Bosch, Xavier; Ramos-Casals, Manuel; Khamashta, Munther A. (2013). Drugs Targeting B-Cells in Autoimmune Diseases. Springer ...
... chronic granulomatous disease, Hodgkin's disease and Wiskott-Aldrich syndrome. More recently non-myeloablative, "mini ... Graft-versus-host disease[edit]. Main article: Graft-versus-host disease. Graft-versus-host disease (GVHD) is an inflammatory ... Veno-occlusive disease[edit]. Severe liver injury can result from hepatic veno-occlusive disease (VOD). Elevated levels of ... Major complications are veno-occlusive disease, mucositis, infections (sepsis), graft-versus-host disease and the development ...
... and IgG4-related disease.[27] There is some evidence that it is ineffective in treating IgA-mediated autoimmune diseases.[28] ... Rituximab is used to treat cancers of the white blood system such as leukemias and lymphomas, including non-Hodgkin's lymphoma ... "Annals of the Rheumatic Diseases. 62 (90002): 55ii-59. doi:10.1136/ard.62.suppl_2.ii55. PMC 1766758. PMID 14532151.. ... Autoimmune diseasesEdit. Rituximab has been shown to be an effective rheumatoid arthritis treatment in three randomised ...
Immunodeficiency Diseases (8th ed.). New York: McGraw-Hill Medical. ISBN 9780071621519.. *^ a b Grimbacher B, Holland S, Gallin ... Rapp-Hodgkin syndrome/Hay-Wells syndrome/Ectrodactyly-ectodermal dysplasia-cleft syndrome 3/Limb-mammary syndrome/OFC8 ... Abnormal neutrophil chemotaxis due to decreased production of interferon gamma by T lymphocytes is thought to cause the disease ... U.S. National Institutes of Health (NIH): Clinical Research Studies: National Institute of Allergy and Infectious Diseases ( ...
Hodgkin's lymphoma. Follicular dendritic cell sarcoma. Extranodal NK/T-cell lymphoma, nasal type. MCPyV Merkel-cell carcinoma. ... Zu Rhein, G.M.; Chou, S.M. (1965). "Particles Resembling Papova Viruses in Human Cerebral Demyelinating Disease". Science. 148 ... Zurhein, G; Chou, S. M. (1965). "Particles Resembling Papova Viruses in Human Cerebral Demyelinating Disease". Science. 148 ( ... the JC virus-induced demyelinating disease of the human brain". Clin. Microbiol. Rev. 25 (3): 471-506. doi:10.1128/CMR.05031-11 ...
Michael Arnold Hodgkin has been awarded "The Order of the Rising Sun, Gold Rays with Rosette" for his contribution to promoting ... Stephen Ira Katz, Director of the National Institute of Arthritis and Musculoskeletal and Skin Diseases Archived 5 March 2012 ...
Text is available under the Creative Commons Attribution/Share-Alike License and the GFDL; additional terms may apply. See Terms of Use for details ...
Hodgkin's disease - holistic medicine - homology (biology) - hormone - host - host factors - HPTN - HPV - HRSA - HTLV-I - HTLV- ... efficacy - empirical - encephalitis - end-stage disease - endemic - endogenous - endoscopy - endotoxin - endpoint - enteric - ... NAT - National Cancer Institute (NCI) - National Institute of Allergy and Infectious Diseases (NIAID) - National Institute of ... HIV disease - HIV prevention trials network (HPTN) - HIV set point - HIV vaccine trials network (HVTN) - HIV-1 - HIV-2 - HIV- ...
Alzheimer's disease,[71] Huntington's disease,[72] Rett syndrome,[73] and dementia,[74] as well as anorexia nervosa[75] and ... "Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to ... "BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases". Nature Reviews. Neuroscience. 14 (6 ... "Neuropsychiatric Disease and Treatment. 5: 433-49. doi:10.2147/ndt.s5700. PMC 2732010. PMID 19721723.. ...
2009) „The birth of cloning: An interview with John Gurdon". Disease Models and Mechanisms 2 (1-2), 9-10. o. DOI:10.1242/dmm. ... Alan Lloyd Hodgkin/Andrew Huxley • 1964: Konrad Emil Bloch/Feodor Lynen • 1965: François Jacob/André Michel Lwoff/Jacques Monod ...
Huntington's disease,[126] Creutzfeldt-Jakob disease,[128] and motor neuron diseases, polyglutamine (PolyQ) diseases, muscular ... particularly some types of non-Hodgkin's lymphoma.[108] Clinical results also seem to justify use of proteasome inhibitor ... including Alzheimer's disease,[125] Parkinson's disease[126] and Pick's disease,[127] amyotrophic lateral sclerosis (ALS),[127] ... Increased levels of proteasome activity correlate with disease activity and have been implicated in autoimmune diseases ...
... cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease ... Scott LJ (March 2017). "Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma". Drugs. 77 (4): 435-445. doi:10.1007/ ... Stein H, Gerdes J, Schwab U, Lemke H, Mason DY, Ziegler A, Schienle W, Diehl V (Oct 1982). "Identification of Hodgkin and ... Horie R, Higashihara M, Watanabe T (Jan 2003). "Hodgkin's lymphoma and CD30 signal transduction". International Journal of ...
... is one such disease, part of an emerging class of diseases called ciliopathies. The underlying cause ... Rapp-Hodgkin syndrome/Hay-Wells syndrome. Elastic/Connective. *Ehlers-Danlos syndromes. *Cutis laxa (Gerodermia ... "Genes and Diseases. NCBI. 1998. Retrieved November 8, 2010.. *^ Ruiz-Perez VL, Ide SE, Strom TM, et al. (2000). "Mutations in a ... Observation of the inheritance pattern has illustrated that the disease is autosomal recessive, meaning that both parents have ...
... and Hodgkin's disease, and less commonly non-Hodgkin's disease.[1] It can be given intravenously, by intramuscular injection, ... Bleomycin is a medication used to treat cancer.[1] This includes Hodgkin's lymphoma, non-Hodgkin's lymphoma, testicular cancer ...
The science of diagnosing and managing plant diseases.. placebo. A substance or treatment of no intended therapeutic value.. ... Hodgkin-Huxley model. A mathematical model that describes how action potentials in neurons are initiated and propagated.. ... disease. Any particular abnormal condition that negatively affects the structure or function of all or part of a living ... Diseases are medical conditions that are often identifiable by specific signs and symptoms. They may be caused by external ...
... known as the Hodgkin-Huxley model. In 1961-1962, Richard FitzHugh and J. Nagumo simplified Hodgkin-Huxley, in what is called ... Neurology works with diseases of the central and peripheral nervous systems, such as amyotrophic lateral sclerosis (ALS) and ... For example, in 1952, Alan Lloyd Hodgkin and Andrew Huxley presented a mathematical model for transmission of electrical ... The scientific study of the biological mechanisms that underlie the disorders and diseases of the nervous system. ...
... and general physiologic processed of central importance in human health and disease.[citation needed] ... 1963 John Eccles / Alan Hodgkin / Andrew Huxley. *1964 Konrad Bloch / Feodor Lynen ...
"Center for Disease Control and Prevention. March 2012. Arquivado dende o orixinal o 01 de maio de 2013. Consultado o 29 de xuño ... Os dous cancros máis comúns asociados co VIH/SIDA son o sarcoma de Kaposi e o linfoma non de Hodgkin relacionado coa SIDA.[151] ... "Center for Disease Control and Prevention. April 2012. Arquivado dende o orixinal o 13 de outubro de 2012. Consultado o 29 de ... "Current opinion in infectious diseases 25 (1): 51-7. PMC 3266126. PMID 22156901. doi:10.1097/QCO.0b013e32834ef5ef.. ...
states that he died of Hodgkin's disease, complicated with uremia, on November 1, 1955. ...
... is used to treat early stage Dupuytren's disease and Ledderhose disease. When Dupuytren's disease is at the ... Fda Approves First Radiopharmaceutical Product To Treat Non-Hodgkin'S Lymphoma Archived January 19, 2009, at the Wayback ... valvular heart disease, coronary artery disease, heart arrhythmia and peripheral artery disease. Radiation-induced fibrosis, ... Cardiovascular disease. Radiation can increase the risk of heart disease and death as observed in previous breast cancer RT ...
Rapp-Hodgkin syndrome/Hay-Wells syndrome/Ectrodactyly-ectodermal dysplasia-cleft syndrome 3/Limb-mammary syndrome/OFC8 ... "What have we learned about GPER function in physiology and disease from knockout mice?". J. Steroid Biochem. Mol. Biol. 153: ...
It is believed that they work through different mechanisms in various diseases. The net effect is probably due to different ... Hodgkin's lymphoma, myelodysplastic syndrome and more. Pomalidomide was submitted for FDA approval on April 26, 2012 and on 21 ... Thus the drug is effective against some inflammatory diseases such as ENL. In 1994 Thalidomide was found to have anti- ... Additionally, inflammatory responses within the bone marrow are believed to foster many hematological diseases. The secretion ...
The drugs vinblastine and vincristine, used to treat Hodgkin's disease, leukemia and other cancers, were derived from the ...
"Jacobsen syndrome , Genetic and Rare Diseases Information Center (GARD) - an NCATS Program". rarediseases.info.nih.gov.. ... Rapp-Hodgkin syndrome/Hay-Wells syndrome. Elastic/Connective. *Ehlers-Danlos syndromes. *Cutis laxa (Gerodermia ... "Jacobsen syndrome , Genetic and Rare Diseases Information Center (GARD) - an NCATS Program". rarediseases.info.nih.gov.. ... Congenital malformations and deformations of integument / skin disease (Q80-Q82, 757.0-757.3) ...
Hodgkin, Douglas I., Frontier to Industrial City:Lewiston Town Politics 1768-1863. Just Write Books, Topsham, ME, 2008 ... Facing annihilation from English attacks and epidemics of new infectious diseases, the Androscoggins started to emigrate to ... Hodgkin, Douglas I., Lewiston Memories: A Bicentennial Pictorial. Jostens Printing & Publishing, 1994 ...
The next most common is primary intraocular lymphoma (PIOL) which is usually non-Hodgkin's, large cell lymphoma of the B-cell ... but a white/yellow dot instead of the red eye reflex can indicate a tumor or some other kind of eye disease. Any photos of a ...
National Institute of Arthritis and Musculoskeletal and Skin Diseases. *National Institute of Biomedical Imaging and ... 1963 John Eccles / Alan Hodgkin / Andrew Huxley. *1964 Konrad Bloch / Feodor Lynen ... National Institute of Allergy and Infectious Diseases. * ... Institute of Diabetes and Digestive and Kidney Diseases. * ...
Hodgkin Disease: UXL Encyclopedia of Diseases and Disorders dictionary. ... Hodgkins Disease , DEFINITION Hodgkins disease is a cancer of the lymphatic (pronounced lim-FAT-ic) system. The lymphatic ... Hodgkin disease, also known as Hodgkin lymphoma or HL, is a cancer of the blood and lymphatic system. It is the most common ... Current research on Hodgkin disease is focused on the possible role of viruses in causing the disease and on exploring newer ...
Hodgkins disease is one of the few cancers that can be successfully treated and cured even if the disease returns. If ... Hodgkins disease is a type of lymphoma. Lymphomas are cancers of the immune system and involve white blood cells. The immune ... Hodgkins disease is an uncommon cancer Although it accounts for less than one percent of cancer in this country, it is one of ... Like most cancers, Hodgkins disease is best treated when diagnosed early. You should see your doctor if you have one of the ...
Hodgkin disease is a type of lymphoma, cancer of the lymph system. It is a rare; but serious condition. Can cause swelling in ... Hodgkin Lymphoma (National Cancer Institute) * What Are the Key Statistics for Hodgkin Disease? (American Cancer Society) Also ... Hodgkins Lymphoma (Mayo Foundation for Medical Education and Research) * What Is Hodgkin Disease? (American Cancer Society) ... The earlier the disease is diagnosed, the more effective the treatment. In most cases, Hodgkin disease can be cured. ...
Remarks on HODGKINS DISEASE A PATHOGENIC AGENT IN THE GLANDS, AND ITS APPLICATION IN DIAGNOSIS ... Remarks on HODGKINS DISEASE. Br Med J 1933; 1 doi: https://doi.org/10.1136/bmj.1.3771.641 (Published 15 April 1933) Cite this ...
... or Hodgkin lymphoma) is an uncommon cancer that occurs in the lymphatic system. It arises when developing lymphocytes develop a ... www.cancer.org/cancer/hodgkindisease/detailedguide/hodgkin-disease-what-is-hodgkin-disease ... Hodgkins Disease (or Hodgkin lymphoma) is an uncommon cancer that occurs in the lymphatic system. It arises when developing ... The symptoms of Hodgkins disease include the following:. *Painless swelling of the lymph nodes commonly in the neck, groin, or ...
Changing priorities in Hodgkins disease.. Br Med J 1980; 280 doi: https://doi.org/10.1136/bmj.280.6227.1310 (Published 31 May ... Royal Brompton and Harefield NHS Foundation Trust: Consultant in Pulmonary Hypertension and Adult Congenital Heart Disease ... Royal Brompton and Harefield NHS Foundation Trust: Consultant Cardiologist in Adult Congenital Heart Disease ...
Hodgkins Disease and Fertility Long-term Side Effects of Radiation for the Treatment of Hodgkins Lymphoma Radiation Dosages ... How often does Hodgkins occur in males in their late 30s or early 40s? Is this disease hereditary? What is Amgen? What is ... Hodgkins disease displays a fairly unique and unusual age predilection: while most cancers tend to occur in one age group ... I was surfing the Net and I thank you for the great Web site about Hodgkins disease. My friends dad was just diagnosed with ...
Hodgkins disease (lymphoma) is a malignant cancer that can affect many organs. A whitish, irregular tumor mass of lymphoma ... Hodgkins disease (lymphoma) is a malignant cancer that can affect many organs. A whitish, irregular tumor mass of lymphoma ... Hodgkins disease - liver involvement. URL of this page: //medlineplus.gov/ency/imagepages/2552.htm Hodgkins disease - liver ...
Carolina Panthers linebacker Mark Fields will miss the 2005 season after a recurrence of Hodgkins disease, his agent said ...
I was diagnosed Hodgkins disease in 1977 and received chemotherapy and radiotherapy. Although it took some months to clear, I ... Will I get Hodgkins disease again?. I was diagnosed Hodgkins disease in 1977 and received chemotherapy and radiotherapy. ... Many would say that you have no more chance of developing Hodgkins disease in the future than anybody else, and when you ... However, you might wish to know that there are two peak age incidences of Hodgkins disease, one in young adulthood and the ...
... more than three sites of disease, bulky mediastinal disease, elevated erythrocyte sedimentation rate [ESR], extranodal extensi ... Patients with early-stage disease and unfavorable prognostic factors (eg, ... Drugs & Diseases , Hematology , Hodgkin Lymphoma Q&A What is early-stage, unfavorable Hodgkin lymphoma (Hodgkin disease)?. ... unfavorable Hodgkin lymphoma (Hodgkin disease)? What to Read Next on Medscape. Related Conditions and Diseases. * Hodgkin ...
This is called Hodgkins disease. The stage of the disease is decided by the extent of this malignant cancer type and the ... Symptoms of Hodgkins Disease. Since both types of Hodgkins disease are malignant in nature they spread and thus symptoms ... This type of cancer is called called Hodgkins disease.. *There are two types of Hodgkins disease, depending on the appearance ... They are Classis Hodgkins disease and NLP (Non-Lymphocyte Predominant) Hodgkins disease. ...
Browse stories and reviews on Anobii of Hodgkins Disease written by Sheila Wyborny, published by Lucent Books in format ...
... on gonadal function in patients treated for Hodgkins disease, we assessed 38 male patients with Hodgkins disease who were , ... Gonadal function following ABVD therapy for Hodgkins disease.. Kulkarni SS1, Sastry PS, Saikia TK, Parikh PM, Gopal R, Advani ...
Etiology of Hodgkins Disease. *. Survey of Viral Oncology with Particular Reference to Lymphomas ... Second, Hodgkins disease in young adults is a chronic granulomatous inflammation, whereas that occurring in persons over 50 is ... First, patients now categorized as having Hodgkins disease include at least 3 subgroups, the etiology of which may be quite ... The epidemiologic features of Hodgkins disease vary with age at clinical onset. Three age periods can be distinguished: 0-14, ...
... was used with success not only in Hodgkins disease but also in refractory / recurrent non-Hodgkins lymphoma.(1,3) The ... Its efficacy in Hodgkins disease is noted in the literature however the results from the University of Florida, for Non- ... 1. Miller AM, Moreb J, Killeen RB: All-oral chemotherapy in refractory Hodgkins disease. Lancet 1991; 337:1408. ... recurrent Hodgkins disease. (1) This protocol was based on an earlier European regimen CEP but, as Prednimustine was ...
... diagnosis of the disease still rests on the identification of the Reed-Sternberg cell. This distinctive, though nonspecific, ... Although there have been many advances in the treatment of Hodgkins disease, ... Hodgkins disease. Cancer 53:232, 1984. 73. List AF, Doll DC, Grew FA: Lung cancer in Hodgkins disease: Association with ... Hodgkins disease; treatment. Appropriate vaccinations. Herpes zoster/varicella. Hodgkins disease; treatment. Systemic ...
Hodgkins disease) - Learn more about the symptoms, risk factors and treatment of this condition that is more common with young ... See a list of publications by Mayo Clinic authors on Hodgkins lymphoma on PubMed, a service of the National Library of ... Learn more: Mayo Clinic facts about coronavirus disease 2019 (COVID-19) Our COVID-19 patient and visitor guidelines, plus ... Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions. ...
the surgical management of Hodgkins Disease and non-Hodgkins lymphomas. Laparoscopic and open techniques are offered for the ... diagnosis and staging of these diseases. When indicated, more extensive resective and ablative procedures are available for ...
Unbeatable Hodgkins Disease website listings at Best of the Web directory. Medical resources at your fingertips: Best of the ... Hodgkins Disease Provides a wealth of information about Hodgkins Disease: definitions, risk factors, symptoms, diagnosis, ... Cancer Treatment Centers: Hodgkins Disease Gives a wealth of general info plus causes, stem cell details, alternative ... Penn State: Hodgkins Disease Presents definitions, causes, risk factors, diagnostic techniques, treatments and self-care tips ...
Hodgkins Disease. Hodgkins disease is a lymphoma, a cancer of the lymphatic system. Hodgkins disease and non-Hodgkins ... Hodgkins disease is slightly more common among males than females. Women who get Hodgkins disease appear to have a slightly ... Hodgkins disease. Description. An in-depth report on the causes, diagnosis, treatment, and prevention of Hodgkins disease. ... Classical Hodgkins Lymphoma. Classical Hodgkins lymphoma accounts for about 95% of Hodgkins disease cases. It has four major ...
... a disease VA recognizes in Veterans as associated with Agent Orange exposure during military service. ... Hodgkins Disease and Agent Orange. Veterans who develop Hodgkins disease (also called Hodgkins lymphoma) and were exposed to ... About Hodgkins disease. Hodgkins disease is one of two common cancers of the lymphatic system, which is part of the immune ... VA benefits for Hodgkins disease. Veterans with Hodgkins disease who were exposed to herbicides during service may be ...
Learn more about symptoms and signs of Hodgkins disease. ... has been undergoing cancer treatment for Hodgkins lymphoma. ... Hodgkins disease, sometimes referred to as Hodgkins lymphoma, and is now in remission following treatment. ... Hodgkins disease is a relatively rare form of cancer that arises from cells of the lymphatic system. The lymphatic system is ... Hodgkins disease can start anywhere in the body, usually taking the form of painless, enlarged lymph nodes. From its origin, ...
Hodgkin disease)?) and How is the Stanford V regimen administered in Hodgkin lymphoma (Hodgkin disease)? What to Read Next on ... Drugs & Diseases , Hematology , Hodgkin Lymphoma Q&A How is the Stanford V regimen administered in Hodgkin lymphoma (Hodgkin ... A prognostic score for advanced Hodgkins disease. International Prognostic Factors Project on Advanced Hodgkins Disease. N ... Hodgkins disease--the role of radiation therapy in advanced disease. Ann Oncol. 1996. 7 Suppl 4:99-103. [Medline]. ...
Etiology of Hodgkins Disease. *. Survey of Viral Oncology with Particular Reference to Lymphomas ...
In their review of the history of the management of stage I/II Hodgkins disease, Drs. Ng and Mauch describe the results of ... In their review of the history of the management of stage I/II Hodgkins disease, Drs. Ng and Mauch describe the results of ... Lymphocyte-predominant Hodgkins disease may be easy to manage from theradiation oncologists viewpoint, as patients with early ... 3. Nadali G, Sarris A, Viviani S, et al: SCD30, progression-free survival(PFS) and survival (surv) in Hodgkins disease (HD) ...
Below is a listing of tumor types that may be confused with Hodgkins disease. Patients diagnosed with Hodgkins disease or the ... True Hodgkins disease is a relatively rare cancer that carries a high probability of a cure. However, the potential for cure ... In up to 60 percent of Hodgkins disease cases, the tumor is found in the area in the chest between the lungs and behind the ... Considered an aggressive lymphoma, it is treated differently than Hodgkins disease but has a high cure rate if appropriately ...
Diseases : Acute lymphoblastic leukemia (ALL), Cancers: Pediatric, Hodgkin Lymphoma, Infant Nutrition: Infant Formula, Leukemia ... Hodgkin Lymphoma, Lung Cancer, Non-Hodgkin Lymphoma, Ovarian Cancer, Pancreatic Cancer, Renal Cancer, Vulvar Cancer ... Hodgkin Lymphoma Related Articles. BREAKING: Bayer Ordered to Pay $2 Billion in Damages in 3rd Roundup-Cancer Trial; Is ... Diseases : Bladder Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal ...
In malignancy, this pathology can be seen at the primary tumour site, particularly in T cell lymphoma and Hodgkins disease, in ... No cases of PAH secondary to a sarcoid-like reaction or Hodgkins disease have been reported previously. This case underscores ... Sarcoid reactions and sarcoidosis in Hodgkins disease and other malignant lymphomata. Br J Cancer1972;26:120. ... Up to 4.4% of patients with carcinoma, 7.3% of patients with non-Hodgkins lymphoma and 13.8% of patients with Hodgkins ...
Girls treated for Hodgkins disease during adolescence acquire a considerable risk of developing breast cancer, as shown by an ... Girls treated for Hodgkins disease during adolescence acquire a considerable risk of developing breast cancer, as shown by an ... The authors estimate that 19% of the girls treated with radiotherapy for Hodgkins disease develop secondary breast cancer ... Breast cancer in young women after treatment for Hodgkins disease. Deutsches Aerzteblatt International ...
  • The disease is named for Thomas Hodgkin (1798-1866), the British doctor who first described it in 1832. (encyclopedia.com)
  • First identified in 1832 in England by Thomas Hodgkin, it is a type of malignant lymphoma. (factmonster.com)
  • It is named after Thomas Hodgkin who first noticed abnormalities in the lymphatic system in 1832. (knowcancer.com)
  • Hodgkin's disease (named after Dr. Thomas Hodgkin, who first recognized it in 1832) and non-Hodgkin's lymphoma . (healthcommunities.com)
  • Hodgkin's disease is a type of lymphoma described by Thomas Hodgkin in 1832 , and characterized by the presence of Reed-Sternberg cells . (academickids.com)
  • In addition, exposure to the defoliant, Agent Orange , has been strongly linked to Hodgkin's disease and other lymphomas. (factmonster.com)
  • The third type of Hodgkin's disease, mixed cellularity, has much more variation in cell type, has rare Reed-Sternberg cells, and may be confused with other lymphomas, especially peripheral T-cell lymphoma. (cancernetwork.com)
  • the surgical management of Hodgkin's Disease and non-Hodgkin's lymphomas. (upenn.edu)
  • Hodgkin's disease and non-Hodgkin's lymphoma are the two types of lymphomas. (umm.edu)
  • Lymphomas are cancers of the lymphatic system-the body's blood-filtering tissues that help to fight infection and disease. (healthcommunities.com)
  • Hodgkin's disease is one of a group of cancers called lymphomas. (cancercompass.com)
  • It is used for treating Hodgkin lymphoma and certain non-Hodgkin lymphomas, such as anaplastic large-cell lymphoma and mycosis fungoides. (goodrx.com)
  • Hodgkin's disease is a unique cancer in many regards but it is classified amongst the lymphomas. (canceradvice.co.uk)
  • Hodgkin's disease is the better-known form of lymphoma (the other lymphomas are grouped into what is called the non-Hodgkin's lymphomas), although Hodgkin's occurs less frequently than non-Hodgkin's. (nyp.org)
  • Ann Arbor staging is the staging system for lymphomas, both in Hodgkin's lymphoma (formerly designated Hodgkin's disease) and non-Hodgkin lymphoma (abbreviated NHL). (wikipedia.org)
  • Thomas RK, Re D, Wolf J, Diehl V. Part I: Hodgkin's lymphoma--molecular biology of Hodgkin and Reed-Sternberg cells. (medscape.com)
  • 2) The resultant all-oral protocol, CCEP, was used with success not only in Hodgkin's disease but also in refractory / recurrent non-Hodgkin's lymphoma. (aahpm.org)
  • Its efficacy in Hodgkin's disease is noted in the literature however the results from the University of Florida, for Non-Hodgkin's lymphoma, were never published. (aahpm.org)
  • Combined radiation and chemotherapy is often used in early-stage Hodgkin's lymphoma, the researchers noted, but its role in advanced disease is less clear. (medpagetoday.com)
  • The disease is less common than non-Hodgkin's lymphoma. (umm.edu)
  • They are generally subdivided into two groups: Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). (umm.edu)
  • Hodgkin's disease is also called Hodgkin's lymphoma. (umm.edu)
  • Classical Hodgkin's lymphoma accounts for about 95% of Hodgkin's disease cases. (umm.edu)
  • Veterans who develop Hodgkin's disease (also called Hodgkin's lymphoma) and were exposed to Agent Orange or other herbicides during military service do not have to prove a connection between their disease and service to be eligible to receive VA health care and disability compensation. (va.gov)
  • There were more data for non-Hodgkin's lymphoma than for Hodgkin's disease in the studies that HMD reviewed, but HMD found that the findings were consistent for the two types of lymphoma. (va.gov)
  • The 38-year-old performer revealed in a statement that he had been diagnosed with Hodgkin's disease , sometimes referred to as Hodgkin's lymphoma , and is now in remission following treatment. (medicinenet.com)
  • Up to 4.4% of patients with carcinoma, 7.3% of patients with non-Hodgkin's lymphoma and 13.8% of patients with Hodgkin's disease will feature sarcoid-like reactions. (bmj.com)
  • Benett MH, MacLennan KA, Vaughan Hudson G, Vaughan Hudson B. Non-Hodgkin's lymphoma arising in patients treated for Hodgkin's disease in the BNLI: a 20-year experience. (springer.com)
  • Variakojis D, Anastasi J. Unresolved issues concerning Hodgkin's disease and its relationship to non-Hodgkin's lymphoma. (springer.com)
  • Nodular sclerosis classical Hodgkin lymphoma is the most common sub-type of Hodgkin's lymphoma , also formerly called Hodgkin's disease . (knowcancer.com)
  • These cells distinguish Hodgkin's disease (HD) from non-Hodgkin's lymphoma (NHL). (healthcommunities.com)
  • Both Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) begin in lymphatic tissues and can invade other organs. (healthcommunities.com)
  • Hodgkin's disease (also called Hodgkin's lymphoma) originates mostly from a swollen lymph node, but can also originate from the bone marrow. (nethealthbook.com)
  • This medicine is used to treat many types of cancer like Hodgkin's disease , non-Hodgkin's lymphoma , mycosis fungoides, and some blood and lung cancers. (goodrx.com)
  • This medicine is used to treat many types of cancer like breast cancer , testicular cancer , Hodgkin's disease , non-Hodgkin's lymphoma , and sarcoma . (goodrx.com)
  • the treatment and prognosis in Hodgkin's lymphoma depend on the stage of disease rather than the histotype. (academickids.com)
  • Hodgkin's disease (now also known as Hodgkin's lymphoma) can be subclassified into four pathologic subtypes based upon Reed-Sternberg cell morphology and the composition of the reactive cell infiltrate seen in the lymph node biopsy specimen. (academickids.com)
  • The purpose of this study was to evaluate the incidence of non-Hodgkin's lymphoma (NHL) as a second tumor in patients treated for Hodgkin's disease (HD), as well as to establish the role of different variables in its appearance. (cun.es)
  • Hodgkin's Lymphoma (Disease) has a colorful history: It was not the first cancer discovered but it was one of the first in which treatments were investigated and ultimately successful. (lymphomainfo.net)
  • Findings of the study, which is the first in the U.S. to investigate BEACOPP, will be presented at the 6th International Symposium on Hodgkin's Lymphoma in Cologne, Germany, the most important international meeting on Hodgkin's disease. (nyp.org)
  • Hodgkin's disease or Hodgkin's lymphoma is a malignant (cancerous) growth of cells in the lymphoid system. (nyp.org)
  • The rare exception are some individuals with very favorable prognosis, Stage I disease, where radiotherapy may be used as definitive therapy in certain selected cases. (healthcentral.com)
  • Epstein reports better survival prognosis for women (Epstein E, Sex as factor in the prognosis of Hodgkins disease. (lymphomainfo.net)
  • Non Hodgkin lymphoma is a lot harder to predict the prognosis of because there are a lot more factors that go into calculating what a specific individual's prognosis is. (healthtap.com)
  • also called Hodgkin s lymphoma) in children and adolescents with radiotherapy and chemotherapy leads to high survival rates but has a number of late effects. (aerzteblatt.de)
  • Hodgkin disease begins when a type of lymphocyte called a B cell turns into an abnormal form called a Reed-Sternberg cell. (encyclopedia.com)
  • There are two basic subtypes of Hodgkin disease: classic, which accounts for 95 percent of cases, and nodular lymphocyte predominant Hodgkin disease (NLPHD), which accounts for the remaining 5 percent. (encyclopedia.com)
  • They are Classis Hodgkin's disease and NLP (Non-Lymphocyte Predominant) Hodgkin's disease. (newsmax.com)
  • The Rye modification divides Hodgkin's disease into four histologic types, named according to their characteristic features: (1) lymphocyte-predominant, (2) nodular sclerosis, (3) mixed cellularity, and (4) lymphocyte-depleted. (cancernetwork.com)
  • Two variants of lymphocyte-predominant disease (nodular and diffuse) have been identified based on different phenotypes and behavioral characteristics. (cancernetwork.com)
  • Nodular lymphocyte-predominant Hodgkin's disease is now widely regarded as a B-cell lymphoma and is the only subtype for which the cell of origin is known, although some investigators contest this conclusion [6-8]. (cancernetwork.com)
  • Finally, the lymphocyte-depleted form of Hodgkin's disease is rare, partly because many of the cases described in the early literature were mistaken for large-cell lymphoma. (cancernetwork.com)
  • Nodular lymphocyte-predominant Hodgkin's disease. (umm.edu)
  • Four controversial unanswered questions about Hodgkin's disease managementneed specific mention ie, treatment of the pregnant patient, the elderlypatient, the patient with lymphocyte-predominant disease, and the patient with aresidual mass after chemotherapy. (cancernetwork.com)
  • Lymphocyte predominant Hodgkin's disease nodular subtype with coexistent "large cell lymphoma. (springer.com)
  • Further phenotypic evidence that nodular, lymphocyte-predominant Hodgkin's disease is a large B-cell lymphoma. (springer.com)
  • Hodgkin's disease associated with chronic lymphocytic leukemia: eight additional cases, including 2 of the nodular lymphocyte predominance type. (springer.com)
  • Biopsy demonstrated IgD-positive nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), which was staged as IIa. (hindawi.com)
  • Final interpretation from both consulting institutions was consistent with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with morphology demonstrating atypical lymphoid cells staining positive for CD20, IgD, CD45, OCT-2, PAX-5, and bcl-6 but negative for CD15 and CD30. (hindawi.com)
  • Lymphocyte-Depleted Classical Hodgkin lymphoma (LDHL) is one of the rarest types of Hodgkin's disease , a variety of blood cancer, comprising only 1 percent of the diagnosed forms of the disease in the world. (knowcancer.com)
  • This clinical trial is studying how well surgery and/or combination chemotherapy with or without radiation therapy or observation only work in treating young patients with newly diagnosed stage I or stage II lymphocyte predominant Hodgkin disease (LPHD). (clinicaltrials.gov)
  • The worst type of Hodgkin's disease to suffer is lymphocyte depleted where the Sternberg-Reed cells predominate and the lymphocytes are hard to come by and there is not a lot of reactive background. (canceradvice.co.uk)
  • Hodgkin disease, also known as Hodgkin lymphoma or HL, is a cancer of the blood and lymphatic system . (encyclopedia.com)
  • Hodgkin begins in the lymphatic system , a group of organs and tissues that are part of the immune system and also help to form new blood cells. (encyclopedia.com)
  • The disease usually spreads from lymph node to lymph node along the lymphatic vessels rather than skipping around the body. (encyclopedia.com)
  • In the later stages of the disease, it spreads outside the lymphatic system to other organs. (encyclopedia.com)
  • Hodgkin's disease, a type of cancer of the lymphatic system . (factmonster.com)
  • Because it affects the lymphatic system, the body becomes less able to fight off infection as the disease progresses. (factmonster.com)
  • Hodgkin's Disease (or Hodgkin lymphoma) is an uncommon cancer that occurs in the lymphatic system. (news-medical.net)
  • Hodgkin's disease is one of two common cancers of the lymphatic system, which is part of the immune system. (va.gov)
  • Hodgkin's disease is a relatively rare form of cancer that arises from cells of the lymphatic system. (medicinenet.com)
  • The lymphatic tissue in Hodgkin's disease contains specific cells (called Reed-Sternberg cells) that are not found in any other types of cancer. (healthcommunities.com)
  • ICD-9 code 201.77 for Hodgkin's disease lymphocytic depletion involving spleen is a medical classification as listed by WHO under the range -MALIGNANT NEOPLASM OF LYMPHATIC AND HEMATOPOIETIC TISSUE (200-208). (aapc.com)
  • Light micrograph of cells from a patient suffering from Hodgkin's disease, a cancer of the lymphatic system. (sciencephoto.com)
  • This sample is from a patient with Stage 4 Hodgkin's disease, which means that the tumour has spread outside the lymphatic system, and has become systemic. (sciencephoto.com)
  • In Hodgkin's disease, cells in the lymphatic system become abnormal. (cancercompass.com)
  • Because lymphatic tissue is present in many parts of the body, Hodgkin's disease can start almost anywhere. (cancercompass.com)
  • Hodgkin's disease may occur in a single lymph node, a group of lymph nodes, or, sometimes, in other parts of the lymphatic system such as the bone marrow and spleen. (cancercompass.com)
  • The lymphatic system is part of the immune system, whose function is to fight disease and infections. (nyhq.org)
  • Hodgkin disease causes the cells in the lymphatic system to abnormally reproduce, which can then form tumors in lymph nodes or other parts of the body. (nyhq.org)
  • Hodgkin publishes his paper on lymphatic disease "On Some Morbid Appearances of the Absorbent Glands and Spleen" Published in Medico-Chirurgical Transactions, the journal of the Medical and Chirurgical Society in London. (lymphomainfo.net)
  • ICD-9 code 201.65 for Hodgkin's disease mixed cellularity involving lymph nodes of inguinal region and lower limb is a medical classification as listed by WHO under the range -MALIGNANT NEOPLASM OF LYMPHATIC AND HEMATOPOIETIC TISSUE (200-208). (aapc.com)
  • Hodgkin's disease (lymphoma) is a malignant cancer that can affect many organs. (medlineplus.gov)
  • Since both types of Hodgkin's disease are malignant in nature they spread and thus symptoms depend on the organs affected by the disease. (newsmax.com)
  • Only chemotherapy helps cure early stages of the disease while radiotherapy is necessary to ensure that the malignant cells are completely destroyed. (newsmax.com)
  • The stage of the disease is decided by the extent of this malignant cancer type and the treatment is also accordingly decided. (newsmax.com)
  • In contrast to some cancers (such as malignant brain tumors and cancer of the pancreas ) that are associated with a very high rates of death, Hodgkin's disease is a potentially curable form of cancer , particularly when diagnosed and treated early in the course of the disease. (medicinenet.com)
  • A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. (mdibl.org)
  • Stage I/II) progression or recurrence at any time, local disease progression or recurrence anytime during or after treatment with AV-PC +/- IFRT, occurrence of a second malignant neoplasm, death from any cause. (clinicaltrials.gov)
  • How much these other cell populations are only reactive and whether the Sternberg-Reed cell is the only malignant cell is still discussed, but what every histologist agrees is that Sternberg-Reed cells or their variants must be present in any biopsy for it to qualify for the diagnosis of Hodgkin's disease. (canceradvice.co.uk)
  • Hodgkin lymphoma (HL) is a heterogeneous group of malignant lymphoid neoplasms of B- cell origin characterized histologically by the presence of Hodgkin and Reed-Sternberg (HRS) cells in the vast majority of cases. (nih.gov)
  • The mitogen-activated protein kinase (MAPK) (also called extracellular signal-regulated kinase [ERK]) pathway has been implicated in malignant transformation and in the regulation of cellular growth and proliferation of several tumor types, but its expression and function in Hodgkin disease (HD) are unknown. (bloodjournal.org)
  • Approximately 1,180 children and adolescents each year are diagnosed with Hodgkin lymphoma in the United States. (curesearch.org)
  • Advantage of proton-radiotherapy for pediatric patients and adolescents with Hodgkin's disease. (annals.org)
  • Hodgkin's disease, although a relatively uncommon malignancy, is one that frequently affects adolescents and young adults. (jaoa.org)
  • The drug regimen BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) has shown to be a safe and effective treatment for children and adolescents with advanced Hodgkin's disease, according to an international pilot study involving more than 200 centers, led by Morgan Stanley Children's Hospital of NewYork-Presbyterian pediatric oncologist Dr. Kara Kelly. (nyp.org)
  • This trial demonstrates that children and adolescents with the disease can now expect improved survival and recovery,' says Dr. Kara Kelly, the study's principal investigator, Associate Attending Pediatrician at Morgan Stanley Children's Hospital of NewYork-Presbyterian and Associate Professor of Clinical Pediatrics at Columbia University College of Physicians & Surgeons. (nyp.org)
  • Children and adolescents with Hodgkin lymphoma have approximately a 94% 5 year survival rate with proper treatment. (healthtap.com)
  • In most cases the disease is diagnosed by a tissue biopsy. (encyclopedia.com)
  • Lymph node biopsy shows the multinucleated Reed-Sternberg cells peculiar to the disease. (factmonster.com)
  • A lymph node biopsy and/or biopsy of the bone marrow is the most reliable way of establishing the diagnosis of Hodgkin's disease. (healthcentral.com)
  • To diagnose Hodgkin disease, doctors use a physical exam and history, blood tests, and a biopsy. (medlineplus.gov)
  • The definitive way to diagnose Hodgkin's disease is via biopsy of the suspected lymph node. (news-medical.net)
  • therefore, allclinicians must exercise caution when ordering a PET scan and should consider itancillary to CT and biopsy for confirmation of persistent or recurrent disease. (cancernetwork.com)
  • However, confusion can arise after biopsy because the cells look very similar to the Reed-Sternberg cells found with Hodgkin's disease. (curetoday.com)
  • It took a biopsy to determine that Tom was suffering from Hodgkin s disease. (arnoldsway.com)
  • If a physician suspects nodular sclerosis classical Hodgkin lymphoma they will need to perform a biopsy to be sure and to determine which classification of lymphoma they are dealing with. (knowcancer.com)
  • Hodgkin disease is diagnosed when abnormal tissue is detected by a pathologist after a biopsy of an enlarged lymph node. (medical-library.net)
  • Clinical data were used to stage the extent of disease at the time of biopsy. (annals.org)
  • A biopsy is needed to confirm the diagnosis of Hodgkin disease and to tell what type it is. (nyhq.org)
  • Hodgkin's disease is curable with chemotherapy, radiation therapy, or a combination of both. (healthcentral.com)
  • While the goal of initial chemotherapy and/or radiation therapy is to put the Hodgkin's disease into a long-term remission and cure the disease, Hodgkin's disease is one of the few cancers that can be successfully treated and cured even if the disease returns. (healthcentral.com)
  • The finding suggests that radiation plays a significant role in the high cure rate for the disease with standard chemotherapy, according to Matthew Sydes, MSc, of the Medical Research Council Clinical Trials Unit in London, and colleagues. (medpagetoday.com)
  • On the other hand, those treated with radiation tended to have more bulk disease at presentation and a lesser response to the chemotherapy, suggesting they should have done worse, Sydes and colleagues argued. (medpagetoday.com)
  • They cautioned that the follow-up is too short for long-term effects of radiation -- such as coronary disease or second malignancies -- to affect future survival figures, so that the impact of the therapy may change. (medpagetoday.com)
  • Chemotherapy and radiation are the main treatments for Hodgkin's disease. (umm.edu)
  • Treatment for Hodgkin's disease includes a combination of radiation and/or chemotherapy . (medicinenet.com)
  • Management of the pregnant patient with Hodgkin's disease has traditionallyinvolved radiation (as if the patient had early-stage disease), followed bydelivery of the infant, and classical staging or adjuvant therapy. (cancernetwork.com)
  • Surgical stagingwith laparotomy (incision through the abdominal wall) and splenectomy (removal of the spleen) are the most accurate means of determining HD spread in patients who show disease above the diaphragm, the large abdominal muscle that controls breathing, and who are candidates for radiation therapy alone. (healthcommunities.com)
  • Most studies of survivors of Hodgkin's disease have shown a low risk for subsequent breast cancer, even though much lower doses of radiation than those used for Hodgkin's disease have been shown to induce breast cancer in other settings. (uni-bonn.de)
  • Women treated for Hodgkin's disease with radiation before 30 years of age are at markedly increased risk for breast cancer, with risk increasing dramatically more than 15 years after therapy. (uni-bonn.de)
  • IMPLICATIONS: The high RR for development of breast cancer in women exposed to therapeutic radiation under 30 years of age raises important issues about optimal treatment strategies for patients with Hodgkin's disease, breast cancer, and other cancers. (uni-bonn.de)
  • Clearly, to minimize the risk [for] cardiovascular disease, doses of both radiation to the heart and anthracyclines should be kept as low as possible without jeopardizing the patient's chance of cure. (healio.com)
  • however, treatment for advanced-stage disease with chemotherapy or radiation therapy (or both) can lead to significant immediate and long-term morbidity, and, while rare, increased mortality from the development of secondary malignancies. (jaoa.org)
  • Women exposed to radiation therapy for Hodgkin's disease have a relative risk 7.7 times greater than the general population of developing breast cancer, according to a study presented at the European Congress of Radiology in Vienna, in March. (diagnosticimaging.com)
  • Dr. Andrea Luparia, from the University of Torino in Italy, and colleagues retrospectively studied 43 women treated with radiation therapy for Hodgkin's disease between 1980 and 2009. (diagnosticimaging.com)
  • For women treated for Hodgkin's disease with radiation therapy, no-dose breast imaging options should be considered, the authors said. (diagnosticimaging.com)
  • In stage I and II treatment of Hodgkin's disease consists of local radiation, which can abort Hodgkin's disease with very good long-term survival rates. (nethealthbook.com)
  • Patients with partial response or stable disease receive radiation therapy and/or continued chemotherapy. (clinicaltrials.gov)
  • The risk of solid tumors, especially breast cancer, is high among women who were treated with radiation for childhood Hodgkin's disease. (uni-bonn.de)
  • Although there have been many advances in the treatment of Hodgkin's disease, diagnosis of the disease still rests on the identification of the Reed-Sternberg cell. (cancernetwork.com)
  • Recently, Carbone et al found that the CD40 antigen is strongly represented on the surface of Reed-Sternberg cells and can help in the distinction between nodular sclerosing Hodgkin's disease and other lymphoid malignancies [5]. (cancernetwork.com)
  • In addition to recognition of the Reed-Sternberg cell, the background cells and their ratio to Reed-Sternberg cells are important in the classification of Hodgkin's disease [1]. (cancernetwork.com)
  • Nodular sclerosis Hodgkin's disease encompasses the lacunar cell variant of the Reed-Sternberg cell. (cancernetwork.com)
  • Hodgkin's disease is distinguished by the presence of large abnormal cells, called Reed-Sternberg cells. (umm.edu)
  • Reed-Sternberg cells are specific to Hodgkin's disease. (umm.edu)
  • Chronic lymphocytic leukemia with coexistent Hodgkin's disease: implication for the origin of the Reed-Sternberg cell. (springer.com)
  • Chronic lymphocytic leukemia/small lymphocytic lymphoma with Reed-Sternberg-like cells and possible transformation to Hodgkin's disease: mediation by Epstein-Barr Virus. (springer.com)
  • Recent work identified Hodgkin and Reed-Sternberg (H/RS) cells in classical Hodgkin's disease (cHD) as clonal progeny of mature B cells. (rupress.org)
  • Hodgkin disease is one of the two major types of lymphoma, a form of cancer that originates in lymphocytes, which are a specific type of white blood cells in the immune system. (encyclopedia.com)
  • Hodgkin lymphoma is a relatively rare form of cancer, affecting two or three people in every 100,000. (encyclopedia.com)
  • According to the National Cancer Institute (NCI), about 8,200 new cases of HL are diagnosed in the United States each year, and 1,350 people die from the disease annually. (encyclopedia.com)
  • Hodgkin's disease is an uncommon cancer Although it accounts for less than one percent of cancer in this country, it is one of the most common cancers in individuals under the age of 35. (healthcentral.com)
  • I was diagnosed Hodgkin's disease (lymph node cancer) in 1977 and received chemotherapy and radiotherapy. (netdoctor.co.uk)
  • There is also a slightly increased risk that patients can develop a second type of cancer, particularly a non-Hodgkin's type of lymphoma (lymph tissue cancer) several years after the successful treatment of the original Hodgkin's disease. (netdoctor.co.uk)
  • This type of cancer is called called Hodgkin's disease. (newsmax.com)
  • In this cancer, based on the nature of cancerous cells, resistant and recurrent types of Hodgkin's disease have also been classified. (newsmax.com)
  • Hodgkin's disease is considered one of the most curable forms of cancer, especially if it is diagnosed and treated early. (umm.edu)
  • True Hodgkin's disease is a relatively rare cancer that carries a high probability of a cure. (curetoday.com)
  • The authors estimate that 19% of the girls treated with radiotherapy for Hodgkin's disease develop secondary breast cancer within 30 years as a result of that therapy. (eurekalert.org)
  • Also, Hodgkin's disease risk was higher for students who had reported early death of a parent, particularly from cancer. (nih.gov)
  • Hodgkin s disease, as quoted by the Merck Manual is a chronic disease with lymphoreticular proliferation of unknown cancer, that may present in localized or disseminated form. (arnoldsway.com)
  • I think of Albert E. Carter in The Cancer Answer , Cancer is not a disease, it is a naturally occurring condition. (arnoldsway.com)
  • LBH589 is an oral pan-deacetylase (DAC) inhibitor, which targets changes in gene function (also known as epigenetic regulation) that regulate processes in the development of cancer, including proliferation and survival of Hodgkin lymphoma cells in laboratory studies(5). (prnewswire.com)
  • This study quantifies the risk of breast cancer following Hodgkin's disease treatment according to age at treatment and type of treatment. (uni-bonn.de)
  • To evaluate the risk of breast cancer from irradiation, we reviewed records of 885 women treated for Hodgkin's disease between 1961 and 1990 (mean follow-up, 10 years). (uni-bonn.de)
  • Patients treated for Hodgkin's disease have an increased risk of developing other types of cancer later in life, especially leukemia. (medical-library.net)
  • Hodgkin lymphoma is the most common cancer of teenagers and young adults. (curesearch.org)
  • By studying patterns of cancer in the population, researchers have found certain risk factors that are more common in people who get Hodgkin's disease than in those who do not. (cancercompass.com)
  • We analyzed possible associations between parity, age at first birth, and the risk of developing Hodgkin's disease by a linkage between the Swedish Cancer Register and a nationwide Fertility Register. (diva-portal.org)
  • Cancer is a group of many related diseases that begin in cells, the body's basic unit of life. (cancercompass.com)
  • Hodgkin's disease, an uncommon lymphoma, accounts for less than 1 percent of all cases of cancer in this country. (cancercompass.com)
  • also called Hodgkin s lymphoma) during childhood or adolescence leaves female patients at considerably increased risk of developing secondary breast cancer (sBC) in early adulthood. (aerzteblatt.de)
  • Hodgkin's disease must be distinguished from non-cancerous causes of lymph node swelling (such as various infections) and from other types of cancer. (academickids.com)
  • Hodgkin's disease accounts for 1% of adult cancer and the incidence in the UK is 2.5 per 100,000 of the population. (canceradvice.co.uk)
  • The American Cancer Society estimates that in 2012 about 9,060 new cases will be diagnosed, and approximately 1,190 people will die from the disease. (nyhq.org)
  • Vitamin D deficiencies have now been linked to an array of diseases and a greatly increased incidence of cancer. (regenerativenutrition.com)
  • Methods: The authors identified 575 patients with Hodgkin disease and 498 with non-Hodgkin lymphoma under the age of 20 years in the Danish Cancer Registry from 1943 to 1994. (rti.org)
  • There are two types of Hodgkin's disease, depending on the appearance of cancerous cells present in the enlarged lymph nodes. (newsmax.com)
  • Other nonspecific markers have been found in Hodgkin's disease, including interleukin-2 receptors, transferrin receptors, and HLA-DR. For these reasons, the diagnosis of Hodgkin's disease should be based on adequate tissue samples and on the opinion of expert hematopathologists [6,7]. (cancernetwork.com)
  • Treatment with alkylating agents, older age at the diagnosis of Hodgkin's disease, recurrence of Hodgkin's disease, and a late stage of disease at diagnosis were risk factors for leukemia. (uni-bonn.de)
  • Treatment depends on how far the disease has spread. (medlineplus.gov)
  • The earlier the disease is diagnosed, the more effective the treatment. (medlineplus.gov)
  • What Happens After Treatment for Hodgkin Disease? (medlineplus.gov)
  • What's New in Hodgkin Disease Research and Treatment? (medlineplus.gov)
  • With modern treatment methods such as the ones you had, radiotherapy and chemotherapy, Hodgkin's disease is curable in the majority of cases and in the early stages is curable in almost all cases. (netdoctor.co.uk)
  • Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (medscape.com)
  • Treatment given to a patient of Hodgkin's diseases depends on the type and stage of the disease. (newsmax.com)
  • Still, it is often used in patients with bulky disease before treatment and in those with residual disease after chemo, they said. (medpagetoday.com)
  • An in-depth report on the causes, diagnosis, treatment, and prevention of Hodgkin's disease. (umm.edu)
  • Visit Medline Plus to learn more about treatment of Hodgkin's disease, the latest research and more from the National Institutes of Health. (va.gov)
  • In their review of the history of the management of stage I/II Hodgkin's disease, Drs. Ng and Mauch describe the results of various treatment protocols and outline the questions posed by ongoing European, Canadian, and American trials. (cancernetwork.com)
  • however, no large database has yet concluded that the PET scan is ofvalue in making treatment decisions for patients with Hodgkin's disease. (cancernetwork.com)
  • Sézary syndrome after successful treatment of Hodgkin's disease. (biomedsearch.com)
  • A patient had a cutaneous T-cell lymphoma, appearing clinically as Sézary syndrome, that developed two years after successful treatment of Hodgkin's disease with combined radiotherapy and chemotherapy. (biomedsearch.com)
  • Tom was diagnosed with Hodgkin s Disease and opted for the standard treatment of chemotherapy. (arnoldsway.com)
  • The choice of regimen is probably best done after considering various pre-treatment factors such as the number of poor prognostic signs, concomitant diseases and individual preferences. (nih.gov)
  • Patients with Hodgkin lymphoma receive high dose mediastinal irradiation at a young age as part of their treatment,' said Dr. Alexander van Rosendael, a medical doctor at Leiden University Medical Centre, the Netherlands. (news-medical.net)
  • We know such treatment reduces the risk of events in non-irradiated patients so it seems likely that it would benefit Hodgkin patients. (news-medical.net)
  • Currently, up to 35% of patients with Hodgkin lymphoma relapse or become refractory after initial treatment, which typically involves at least two regimens of combination chemotherapy along with high-dose chemotherapy and stem cell transplant(2). (prnewswire.com)
  • Treatment options for Hodgkin lymphoma typically involve an initial round of combination chemotherapy, but standard frontline treatments do not lead to long-term disease-free survival in all patients(3,4). (prnewswire.com)
  • Treatment for nodular sclerosis classical Hodgkin lymphoma depends on the age and sex of the patient. (knowcancer.com)
  • Unfortunately there are cases of relapse and some studies indicate that treatment for nodular sclerosis classical Hodgkin lymphoma can lead to other health complications later in life. (knowcancer.com)
  • Regular follow-up examinations are important after treatment for Hodgkin's disease. (medical-library.net)
  • For the individual patient with this disease , this approach enables treatment-specific risk counselling and follow-up programs tailored to the individual," Maja V. Maraldo, MD, a resident in clinical oncology at Rigshospitalet in Copenhagen, Denmark and colleagues wrote. (healio.com)
  • For more information on Hodgkin's disease, its symptoms, the treatment options available and much more, take some time to explore the rest of this site. (cancercompass.com)
  • Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. (clinicaltrials.gov)
  • This does not, however, hide the fact that certain important matters are still not clear, in particular the cause of the disease, its essential nature and, indeed, the best method for its treatment. (springer.com)
  • The purpose of this study is to determine whether a blood test can accurately detect whether if the participant's lymphoma has come back after completion of initial chemotherapy treatment for their aggressive B-cell Non-Hodgkin lymphoma. (centerwatch.com)
  • Like most cancers, Hodgkin's disease is best treated when diagnosed early. (healthcentral.com)
  • Hodgkin's disease displays a fairly unique and unusual age predilection: while most cancers tend to occur in one age group Hodgkin's disease demonstrates a bimodal distribution. (oncolink.org)
  • As with many other cancers the causative factors of Hodgkin's disease may be genetic, environmental, dietary or a combination of all three. (oncolink.org)
  • The incidence of Hodgkin's disease is about 4/100,000 people/year, and accounts for a bit less than 1% of all cancers worldwide. (academickids.com)
  • Different diseases, including cancers, have different risk factors. (nyhq.org)
  • While Hodgkin's disease is one of the most curable cancers, treatments for advanced forms of the disease leave room for improvement. (nyp.org)
  • There are approximately 625 cases of childhood Hodgkin's disease (5 percent of all childhood cancers) diagnosed in the U.S. every year. (nyp.org)
  • First, patients now categorized as having Hodgkin's disease include at least 3 subgroups, the etiology of which may be quite distinct. (aacrjournals.org)
  • Survival from pediatric Hodgkin disease now exceeds 85%, resulting in a growing cohort of survivors who may be at risk for late effects. (acco.org)
  • Because at first only a few cases of sBC were identified in the long-term follow-up of pediatric HD trial patients ( 17 ), for a long time in Germany the available data were insufficient to justify including this risk group in an intensive screening program for early disease. (aerzteblatt.de)
  • A cohort of 30 patients with newly diagnosed Hodgkin s disease was studied. (scielo.br)
  • Hodgkin's disease is often treated with combination chemotherapy and radiotherapy. (oncolink.org)
  • I was diagnosed Hodgkin's disease in 1977 and received chemotherapy and radiotherapy. (netdoctor.co.uk)
  • Current late effects screening recommendations are largely based on studies of Hodgkin disease survivors treated in the earlier era of chemotherapy and radiotherapy, and may not be applicable to more contemporarily treated patients. (acco.org)
  • These organs produce, store and carry white blood cells to fight infection and disease. (curesearch.org)
  • It helps the body fight disease and infection. (cancercompass.com)
  • Cells that fight infection and disease. (nyhq.org)
  • Infection with the Epstein-Barr virus, which causes mononucleosis (also called mono ) has been linked to Hodgkin disease. (nyhq.org)
  • Infection with this virus, which cases AIDS, has also been linked to an increased risk of Hodgkin disease. (nyhq.org)
  • Because infections usually occur seasonally, the authors looked at the seasonal pattern of occurrence of these diseases, since seasonal variation in occurrence would lend support to the hypothesis of an etiologic link between infection and lymphoma. (rti.org)
  • About 10 - 15% of Hodgkin's disease cases are diagnosed in children and teenagers. (umm.edu)
  • Hodgkin lymphoma is most commonly diagnosed in teenagers and adults between the ages of 15 and 35 and in adults over 50(7). (prnewswire.com)
  • The majority of Hodgkin lymphoma cases are in teenagers (age 15-19). (curesearch.org)
  • There are many different subtypes of non-hodgkin lymphoma . (healthtap.com)
  • Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. (medscape.com)
  • MacLennan et al have divided nodular sclerosing Hodgkin's disease into grade-1 and grade-2 histology because they found differences in disease-free and overall survival rates between the two grades [9]. (cancernetwork.com)
  • Many patients with late-stage Hodgkin's disease also have good odds for survival. (umm.edu)
  • Long Survival in Hodgkin's Disease. (annals.org)
  • Determine the objective response rate, response duration, and survival of patients receiving lomustine/etoposide/cyclophosphamide/procarbazine (CECP) for stage IIB-IV AIDS-related Hodgkin's disease. (clinicaltrials.gov)
  • Nodular sclerosis Hodgkin's disease may be difficult to distinguish from large-cell lymphoma, especially if there are many lacunar cells. (cancernetwork.com)
  • Men are more likely than women to get nodular sclerosis classical Hodgkin lymphoma. (knowcancer.com)
  • What differentiates nodular sclerosis classical Hodgkin lymphoma from other types of lymphoma is that it has large tumor nodules with varying degrees of sclerosis. (knowcancer.com)
  • One of the first signs of nodular sclerosis classical Hodgkin lymphoma is enlarged lymph nodes. (knowcancer.com)
  • Nodular sclerosis classical Hodgkin lymphoma, like other types of lymphoma, is diagnosed and staged based on characteristics of the disease. (knowcancer.com)
  • As an example, stage 1 nodular sclerosis classical Hodgkin lymphoma is in the early stages and only affects one lymph node site. (knowcancer.com)
  • Stage 4 nodular sclerosis classical Hodgkin lymphoma affects several sites and has spread to organs. (knowcancer.com)
  • Due to very high rates of early detection people who have nodular sclerosis classical Hodgkin lymphoma have high recovery rates. (knowcancer.com)
  • Overall, it is more common in males, except for the nodular sclerosis variant (see below) of Hodgkin disease, which is more common in women. (academickids.com)
  • Gutensohn N, Cole P. Childhood social environment and Hodgkin's disease. (medscape.com)
  • Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. (medscape.com)
  • Increased sun exposure of children may also be associated with a decreased risk of developing both childhood non Hodgkin and Hodgkin lymphoma. (greenmedinfo.com)
  • Risk ratios of Hodgkin's disease tended to be lower for men who had experienced various common contagious diseases in childhood. (nih.gov)
  • or 3) early childhood infections eliminated some subjects who otherwise would have attended college and ultimately developed adult-onset Hodgkin's disease. (nih.gov)
  • Surviving spouses, dependent children and dependent parents of Veterans who were exposed to herbicides during military service and died as the result of Hodgkin's disease may be eligible for survivors' benefits . (va.gov)
  • Hodgkin lymphoma survivors have more severe coronary artery disease 20 years after chest irradiation, according to research presented today at ICNC 2017. (news-medical.net)
  • The current study assessed the extent, severity, and location of coronary artery disease (CAD) in Hodgkin lymphoma survivors who had received chest irradiation. (news-medical.net)
  • This is an important study for survivors of Hodgkin disease who were treated from 1987 to the present. (acco.org)
  • TheInternational Prognostic Index (IPI) for advanced-stage disease has been appliedto the management of early-stage disease and may be useful in this setting.Other groups, basing their efforts on the early work of Specht, have attemptedto better measure tumor burden and the number of involved sites, especially foradvanced disease treated with chemotherapy. (cancernetwork.com)
  • In up to 60 percent of Hodgkin's disease cases, the tumor is found in the area in the chest between the lungs and behind the breastbone, known as the mediastinum. (curetoday.com)
  • Below is a listing of tumor types that may be confused with Hodgkin's disease. (curetoday.com)
  • Patients diagnosed with Hodgkin's disease or the following tumor types should consider seeking confirmation of an accurate diagnosis. (curetoday.com)
  • Abnormal coagulation test results followed the course of disease, normalizing with tumor regression and reappearing during relapse. (biomedsearch.com)
  • EAST HANOVER, N.J. , Dec. 6, 2010 /PRNewswire/ -- The Novartis Pharmaceutical Corporation ('Novartis') oral investigational drug LBH589 (panobinostat) demonstrated substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients who had relapsed or had become refractory after an autologous stem cell transplant, according to new data from a Phase II clinical trial presented today(1). (prnewswire.com)
  • In this pivotal single-arm study, one of the largest ever conducted in this patient population, 82% (n=106) of patients, most in their fifth line of therapy or beyond, achieved disease control (defined as stable disease or better) and 74% (n=96) achieved tumor reduction at a median follow-up of 9.6 months, demonstrating the sustained anticancer activity of LBH589. (prnewswire.com)
  • Ninety-nine children with Stage IV Hodgkin's disease or Stage IIB/IIIB Hodgkin's disease with bulk disease (presence of a tumor of 6 cm or greater) were enrolled in the study. (nyp.org)
  • Management of the elderly patient with Hodgkin's disease also remainssomewhat risky. (cancernetwork.com)
  • We have recently studied the case of a patient with Hodgkin's disease with hypercalcemia and increased calcitriol levels. (annals.org)
  • An insulin-related growth-promoting substance was detected in the serum of a patient with Hodgkin's disease who suffered from severe hypoglycaemia, as well as in the supernatant of homogenized spleen tissue of the same patient. (springer.com)
  • The Health and Medicine Division (HMD) (formally known as the Institute of Medicine) of the National Academy of Sciences, Engineering, and Medicine concluded in its 1994 report on " Veterans and Agent Orange: Health Effects of Herbicides Used in Vietnam " and in future updates that there is sufficient evidence of a positive association between exposure to the herbicides used in Vietnam and the development of Hodgkin's disease. (va.gov)
  • There have been numerous epidemiologic reports citing a number of factors associated with the increased risk for the development of Hodgkin's disease. (jaoa.org)
  • This report describes the development of Hodgkin's disease in two brothers and discusses factors associated with the increased risk of development of Hodgkin's disease, particularly in these cases. (jaoa.org)
  • Although uncontrolled confounding might have affected our results, they do not indicate that hormonal or immunological changes associated with childbearing play a role in the development of Hodgkin's disease. (diva-portal.org)
  • The causes of Hodgkin's disease remain incompletely known, but a higher incidence in men than in women has prompted an interest in the role of female sex hormones and reproductive history. (diva-portal.org)
  • Patients with a history of past EB virus related mononucleosis have a higher incidence of later Hodgkin's disease and EB virus is detectable within the RS cells in at least 50% of cases of the disease, particularly those with mixed cellularity Hodgkin's disease. (canceradvice.co.uk)
  • The Late Effects Study Group followed a cohort of 1380 children with Hodgkin's disease to determine the incidence of second neoplasms and the risk factors associated with them. (uni-bonn.de)
  • This study compared the prevalence and incidence of general illnesses between patients with non-Hodgkin lymphoma (NHL) and a control group. (ovid.com)
  • In Hodgkin's disease, lymphocytes grow abnormally within the lymph nodes and can involve the other organs of the immune system. (healthcentral.com)
  • This is decided based on the stage of the diseases and the organs to which lymphoma has spread. (newsmax.com)
  • In malignancy, this pathology can be seen at the primary tumour site, particularly in T cell lymphoma and Hodgkin's disease, in lymph nodes draining the region, or in distant organs such as the spleen, liver or bone marrow. (bmj.com)
  • Hodgkin disease cells can also spread to other organs. (nyhq.org)
  • In the early 1990s the University of Florida developed an 'all-oral' protocol for use in refractory / recurrent Hodgkin's disease. (aahpm.org)
  • 1. Miller AM, Moreb J, Killeen RB: All-oral chemotherapy in refractory Hodgkin's disease. (aahpm.org)
  • Almost all cases of Hodgkin's disease is treated with combination chemotherapy. (healthcentral.com)
  • Stage III and IV patients of these patients with low-grade Hodgkin's disease were first treated with combination chemotherapy and then with radiotherapy, if indicated. (nethealthbook.com)
  • PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy with lomustine, etoposide, cyclophosphamide, and procarbazine in treating patients with stage IIB, stage III, or stage IV AIDS-related Hodgkin's disease. (clinicaltrials.gov)
  • NLPHD differs from classic Hodgkin diseae in that it occurs primarily in lymph nodes in the neck and armpits, and its large abnormal cells are known as "popcorn" cells because they look like pieces of popped popcorn under the microscope. (encyclopedia.com)
  • The most common symptom of Hodgkin's disease is a painless swelling in the lymph nodes in the neck, underarm, or groin. (medical-library.net)
  • There are however some long-term effects of the therapy that is used for Hodgkin's disease that are uncommon but worth knowing about. (netdoctor.co.uk)
  • Hodgkin's disease is an uncommon disorder. (cancernetwork.com)
  • Although researchers know that Hodgkin disease begins with the formation and multiplication of abnormal cells, they do not yet know what triggers this formation. (encyclopedia.com)
  • Abnormal coagulation results in patients with Hodgkin's disease. (biomedsearch.com)
  • We conclude that the antioxidant system is impaired in Hodgkin's disease due to the abnormal metabolism of trace elements and antioxidant enzymes. (nih.gov)
  • Rapp-Hodgkin syndrome is a form of ectodermal dysplasia , a group of about 150 conditions characterized by abnormal development of ectodermal tissues including the skin, hair, nails, teeth, and sweat glands. (nih.gov)
  • As of 2008, there were about 500,000 people in the United States with some form of lymphoma, but only 143,000 had Hodgkin disease. (encyclopedia.com)
  • HD usually starts in B cell lymphocytes located in lymph nodes in the neck area, although any lymph node may be the site of initial disease. (umm.edu)
  • Rapp-Hodgkin syndrome has signs and symptoms that overlap considerably with those of ankyloblepharon-ectodermal defects-cleft lip/palate (AEC) syndrome . (nih.gov)
  • What Are the Risk Factors for Hodgkin Disease? (medlineplus.gov)
  • Whilst the risk is very small indeed, it is a good thing to be aware of this and to report any symptoms of malaise, fever, weight loss or enlarged lymph glands, although of course the chances are that there will be an explanation for these symptoms than your original Hodgkin's disease. (netdoctor.co.uk)
  • Certain types of viral infections may increase the risk of Hodgkin's disease. (umm.edu)
  • 18] For example, older patients sometimescannot receive doxorubicin or bleomycin because of the presence or risk ofcardiac or pulmonary disease. (cancernetwork.com)
  • Combined fruit and vegetable consumption was associated with decreased non-Hodgkin lymphoma risk. (greenmedinfo.com)
  • Consumption of red and processed meat may be related to non-Hodgkin lymphoma risk. (greenmedinfo.com)
  • He continued: 'What was remarkable was that irradiated patients had all the features of high-risk CAD, including high stenosis severity, proximal location, and extensive disease. (news-medical.net)
  • PA nobinostat T rial in H odgkin's lymphoma) has begun enrollment, investigating the drug as a maintenance therapy following autologous stem cell transplant in patients with Hodgkin lymphoma who have an increased risk for relapse(6). (prnewswire.com)
  • All subjects will receive a comprehensive risk-adapted clinical evaluation using the COG Late Effects Screening Guidelines as appropriate for Hodgkin disease and specifi c therapeutic exposures. (acco.org)
  • Scientists at hospitals and medical centers all across the country are studying Hodgkin's disease risk factors. (cancercompass.com)
  • However, most people with these risk factors do not get Hodgkin's disease, and many who do get Hodgkin's disease have none of the known risk factors. (cancercompass.com)
  • We found a slightly and nonsignificantly reduced risk of Hodgkin's disease in ever-parous compared with nulliparous women. (diva-portal.org)
  • A risk factor is anything that may increase a person's chance of developing a disease. (nyhq.org)
  • Although these factors can increase a person's risk, they do not necessarily cause the disease. (nyhq.org)
  • But, knowing your risk factors to any disease can help to guide you into the appropriate actions, including changing behaviors and being clinically monitored for the disease. (nyhq.org)
  • Patients who survive Hodgkin's disease are at increased risk for second neoplasms. (uni-bonn.de)
  • Dr. Kelly, who is a member of the Children's Oncology Group Hodgkin's Committee, will chair the next High-Risk Hodgkin's disease trial, which is currently under development. (nyp.org)
  • Purpose: Infections have been hypothesized to be a risk factor for Hodgkin disease and non-Hodgkin lymphoma. (rti.org)
  • The cause of Hodgkin's disease is unknown, although it is believed to be associated with certain viruses commonly noted in the population. (healthcentral.com)
  • Hodgkin lymphoma most commonly affects adults in their early 20s and adults over 70 years old. (news-medical.net)
  • Males are affected by the disease more commonly than females and in the ratio of 1.4:1. (canceradvice.co.uk)
  • In some cases, a patient with classic Hodgkin has no early symptoms, and the disease is discovered during a routine chest x ray. (encyclopedia.com)
  • In most cases, Hodgkin disease can be cured. (medlineplus.gov)
  • Many would say that you have no more chance of developing Hodgkin's disease in the future than anybody else, and when you consider that the number of new cases diagnosed every year in the UK is about 1500, this is clearly a very small chance indeed. (netdoctor.co.uk)
  • Among women born between 1925 and 1972, 917 cases with Hodgkin's disease and concomitant fertility information were identified. (diva-portal.org)
  • There is a 1.4:1 male sex preponderance over females with the disease and almost three quarters of all cases have presented by 60 years of age. (canceradvice.co.uk)
  • Epstein-Barr virus (EBV), a lymphotropic herpesvirus that is widespread in the human population, is associated with approximately 40% of Hodgkin s disease cases. (scielo.br)
  • Every student and every doctor knows that cases of Hodgkin's disease may show a fever that is high for one week and low for the next week and so on. (wikipedia.org)
  • Swollen lymph nodes are a common symptom of colds and flus, but in Hodgkin disease, the lymph nodes are usually larger than those that occur with common infections, and they do not shrink when treated with standard medications like antibiotics. (curesearch.org)
  • The symptoms of Hodgkin disease may resemble other blood disorders or medical problems, such as influenza or other infections. (nyhq.org)
  • People who are concerned about the chance of developing Hodgkin's disease should talk with their doctor about the disease, the symptoms to watch for, and an appropriate schedule for checkups. (cancercompass.com)